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ABSTRACT 
BACKGROUND 
Chronic periodontitis is an inflammatory oral disease which leads to the destruction of the 
supporting tissues of the teeth, leading to bone resorption and tooth loss. Destruction of the 
periodontal attachment apparatus can result in gingival recession and root furcation exposure 
in advanced stages resulting in tooth mobility and tooth loss. Mechanical debridement is the 
most frequent treatment for chronic periodontitis, in severe cases systemic antibiotics in 
conjunction with mechanical debridement have been used. The efficacy and the beneficial 
effect of this combination on the inflammatory biomarkers require further investigation. 
OBJECTIVES 
The aim of this systematic review was to assess the effectiveness of adjunctive antibiotics in 
the improvement of inflammatory systemic biomarkers in the treatment chronic periodontitis. 
SEARCH METHODS 
We searched the following electronic databases: Cochrane Oral Health Group Trials Register 
(30th June 2018). The Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane 
Library 2018 – current issue), MEDLINE (1966 to present), EMBASE (1982 to present), 
CINAHL via EBSCO (1990 -present), Google scholar (1990 - present). Web of Knowledge 
(1990 to May 2018), The meta-Register of Controlled Trials (www.controlled-trials.com), The 
US National Institutes of Health On-going Trials Register (www.clinicaltrials.gov). The World 
Health Organization International Clinical Trials Registry platform (www.who.int/trialsearch) 
was searched to identify relevant trials for inclusion in the review. Conference proceedings, 
on-going trials registers (02/06/2018) and reference list of included articles were assessed for 
relevant trials. No language or date of publication restrictions applied. 
SELECTION CRITERIA 
We searched for randomised controlled trials (RCTs that evaluated the effectiveness of 
adjunct antibiotic therapy on the systemic biomarkers in the treatment of chronic periodontitis. 
All trials that compared adjunctive systemic antibiotics with mechanical debridement or 
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mechanical debridement alone, or scaling and root planning, oral hygiene and prophylaxis or 
placebo were included in the study. 
DATA COLLECTION AND ANALYSIS 
Two reviewers independently examined the titles and abstracts retrieved by the search to 
identify relevant trials for inclusion in the review. All included trials were assessed for risk of 
bias and data were extracted for further analysis. The primary outcomes assessed 
include:changes in serum/blood levels of inflammatory biomarkers such as Matrix 
Metalloproteinases (MMPs), Tissue Inhibitors of MMPs(TIMs), Cytokines, C-Reactive 
Protein(CRP) and Glycated haemoglobin(HbA1c). Secondary outcomes include periodontal 
indices such as bleeding on probing (BOP), gingival index (GI), clinical attachment level 
(CAL), plaque index (PI) and probing pocket depth (PPD). 
MAIN RESULTS
Fourteen trials (n=1457 participants) were included in the review. Seven trials reported on 
MMP-8, with average of 3 months time to event. Five trials reported on IL-1β, three trials on 
IL-6 and two on IL-8 serum level. Four trials reported on CRP; while eight reported on HbA1c 
level and one on TIMP-1 level. Trials were assessed for risk of bias and judged as low, high, 
or unclear of risk of bias.  
Six studies showed no significant differences in MMP-8 concentration level between the two 
intervention groups. Significant decrease (60%) in odds of increased MMP-8 levels during 2-
year study was reported in one trial (OR 0.40, 95%CI: 0.21 to 0.77, p=0.006). One study 
reported no significant difference for TIMP-1 (0.96, 95% CI: 0.78 to 1.18, p=0.7), while two 
studies showed significant reduction in HbA1c (10%) at 3 months. Other studies reported no 
difference in HbA1c levels (%): (Mean (SD) 7.00 (0.76) versus 7.11 (0.99); p=0.710), (Median 
(Interquartile Range [IQR]) 6.3 (5.5,7.3) versus 6.7 (6.3,  7.7); p=0.8), (p=0.35, 0.55, 0.33, 
and 0.62, at baseline, 3 months, 6 months, and after 1 year of treatment respectively. Meta-
analysis showed a mean reduction of 0.24mm in the periodontal pockets (PD) at 3 months 
[MD, -0.25 with 95% CI -0.38 to -0.12]. Two trials revealed no significant difference PD≤3mm 
at 3 months, [MD, -1, 95% CI -22.54 to 20.53 (p=0.19)]. A decrease in periodontal 
pockets(PD≥4mm) and a reduction of 3.38mm in favour of SRP+antibiotics after 3 months 
[MD, -3.38, 95% CI -6.51 to -0.25 (p=0.93, I2=0%)] was observed for probing depth(PD). No 
significant difference in clinical attachment level (CAL) at 3 months [MD, -0.13, 95% CI -0.34 
to 0.07; Chi2=0.98, df=3, p=0.81, I2=0%]. The overall quality of evidence was low largely 
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because of attrition bias (24%; 32%) connoting high risk of bias and wide confidence intervals 
which suggests imprecision of results. 
AUTHORS' CONCLUSIONS: 
There is limited but low-level of evidence suggesting that systemic antibiotic therapy 
combined with mechanical debridement improves the systemic biomarker levels during the 
treatment of chronic periodontitis. 
Samevatting 
Agtergrond 
Chroniese periodontitis is ‘n inflammatoriese mondsiekte  wat lei tot die vernietiging van die 
ondersteunende weefsel van die tande, en uiteindelik tot beenresorpsie en tandverlies. 
Vernietiging van die periodontale hegtingsorgane kan lei tot tandvleis-terugsakking en 
wortelaftakking-ontbloting en, in meer gevorderde stadiums, potensieel tot tandmobiliteits- en 
tandverlies. Tandsteenverwydering en wortelbeplanning, ook bekend as meganiese 
brokstukverwydering, is die behandeling wat die meeste op chroniese periodontitis toegepas 
word. Vir ernstige gevalle van periodontale siektes, is sistemiese antibiotika tesame met 
skalering en wortelbeplanning gebruik; die doeltreffendheid hierdie kombinasie benodig 
verdere ondersoek oor die voordelige uitwerking op die vlak van inflammatoriese biomerkers.  
Doelwitte 
Die doel van hierdie sistematiese oorsig was om die effektiwiteit van adjunktiewe 
(bykomende) antibiotika in die verbetering van inflammatoriese sistemiese biomerkers in die 
behandeling van chroniese periodontitis te assesseer. 
Soekmetodes 
Ons het deur die volgende elektroniese databasisse gesoek: Cochrane Oral Health Group 
Trials Register (30 Junie 2018), The Cochrane Central Register of Controlled Trials (Trials 
(CENTRAL) (Cochrane Library 2018 – jongste uitgawe), MEDLINE (1966 tot hede), EMBASE 
(1982 tot hede), CINAHL via EBSCO (1990 – hede), Google scholar (1990 – hede). Web of 
Knowledge (1990 tot Mei 2018), The meta-Register of Controlled Trials (www.controlled-
trials.com), The US National Institutes of Health On-going Trials Register 
(www.clinicaltrials.gov). The World Health Organization International Clinical Trials Registry 
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platform (www.who.int/trialsearch) is ondersoek om relevante proefnemings vir insluiting in 
die oorsig te identifiseer. Relevante konferensieprosedures, deurlopende 
proefnemingsregisters (02/06/2018) en verwysingslyste van ingeslote artikels is vir relevante 
proefnemings geassesseer. Geen beperkings is geplaas op die taal of datum van publikasie 
toe die elektroniese databasisse ondersoek is nie. 
Seleksiekriteria 
Ons het gesoek na lukraak gekontroleerde proefnemings (RCT’s) wat die effektiwiteit van 
adjunkte antibiotiese terapie op die sistemiese biomerkers in die behandeling van chroniese 
periodontitis geëvalueer het. Alle geïdentifiseerde RCT’s wat adjunktiewe sistemiese 
antibiotika met meganiese verwydering alleen of met skalering en wortelbeplanning, 
mondhigiëne en profilakse of plasebo vergelyk, is in die studie ingesluit. 
Dataversameling en -analise 
Twee ondersoekende outeurs het onafhanklik van mekaar die titels en abstrakte bestudeer 
wat deur die soektog opgespoor is om die ingeslote proefnemings te selekteer. Elke ingeslote 
soektog is geassesseer vir risiko van vooroordeel (Sien risiko van vooroordeel-tabel) en 
relevante data is vir verdere analise onttrek. Ons primêr geassesseerde uitkomste is: 
veranderings in serum/bloedvlakke van inflammatoriese biomerkers soos (Matrix 
Metalloproteinases) MMPs, (Tissue Inhibitors of MMPs) TIMs, Cytokines, C-Reactive 
Protein(CRP) en Glycated haemoglobin (HbA1c). Sekondêre uitkomste sluit in periodontale 
aanduiders soos bloeding by ondersoek (BOP), tandvleis-indeks (GI), kliniese 
aanhegtingsvlak (CAL), plaak-indeks (PI) en diepte van ondersoek (PPD). 
Belangrikste resultate 
Veertien proefnemings (n=1457) is in die ondersoek ingesluit. Alle proefnemings het 
antibiotika versus plasebo gekombineer met meganiese verwydering vergelyk. Sewe 
proefnemings het MMP-8 gerapporteer, met ‘n gemiddelde van 3 maande tot ryd van uitslag. 
Vyf proefnemings op IL-β, drie proefnemings op IL-6 en twee op IL-8 serumvlak. Daar is vier 
proefnemings op CRP gerapporteer; agt op HbA1c vlak en een op TIMP-1 vlak. 
Proefnemings is geassesseer vir risiko van partydigheid en geoordeel as synde laag, hoog, of 
onduidelik weens risiko van strydigheid. Ses studies het geen noemenswaardige verskille in 
MMP-8 konsentrasievlak tussen twee intervensiegroepe aangetoon nie. ‘n Aansienlike 
afname (60%) in verskille van verhoogde MMP-8 vlakke gedurende ‘n 2-jaarstudie is in een 
ondersoek (OR 0.40, 95%CI: 0.21 tot0.77, p=0.006) gerapporteer. Een studie het gewys op 
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een nie-opvallende verskil vir TIMP-1 (0.96, 95% CI: 0.78 tot 1.18, p=0.7). Slegs twee studies 
het aansienlike verlaging in HbA1c (10% verlaging op 3 maande) aangetoon, terwyl ander 
geen opvallende verskil in HbA1c-vlakke aangetoon het nie (%): (Gemiddelde (SD) 7.00 
(0.76) versus 7.11 (0.99); p=0.710), (Mediaan (Interkwartiel-omvang [IQR]) 6.3 (5.5,7.3) 
versus 6.7 (6.3 7.7); p=0.8), (p=0.35, 0.55, 0.33, en 0.62, op 3 maande, 6 maande, en ná 1 
jaar van behandeling onderskeidelik. ‘n Studie het na 3 maande (1.5%) versus (0.9%) 
aangetoon; geen aansienlike verskil op 3 maande nie (p=0.22). Meta-analise vertoon ‘n 
gemiddelde verlaging van 0.24mm in die periodontale sakke (PD) op 3 maande [MD, -0.25 
met 95% CI -0.38 tot -0.12], terwyl twee proefnemings geen beduidende verskil PD≤3mm op 
3 maande, [MD, -1 met 95% CI -22.54 tot 20.53 (p=0.19)] aangetoon het nie. ‘n Afname in 
periodontale sakke (PD≥4mm) en ‘n verlaging van 3.38mm ten gunste van die SRP + 
antibiotika na 3 maande [MD, -3.38 met 95% CI -6.51 tot -0.25 (p=0.93; I2=0%)])] is vir 
ondersoekdiepte (PD) waargeneem. Geen aansienlike verskil in kliniese hegtingsvlak (CAL) 
op 3 maande [MD, -0.13 op 95% CI -0.34 tot 0.07; Chi2=0.98, df=3, p=0.81, I2=0%]. Gehalte 
van bewys is geassesseer deur GRADEpro en het lae voorkoms van effektiwiteit van 
adjunkte sistemiese antibiotika in die behandeling van chroniese periodontitis aangetoon. 
Skrywers se gevolgtrekkings 
Daar is beperkte maar laevlak-bewyse wat suggereer dat sistemiese antibiotiese terapie 
gekombineer met meganiese verbrokkeling die sistemiese biomerkervlakke gedurende die 
behandeling van chroniese periodontitis verbeter. 
ABBREVIATIONS 
CRP: C-reactive protein; CVD: cardiovascular disease; DM2: diabetes mellitus type2 
GCF: gingival crevicular fluid; HbA1c: glycosylated haemoglobin; IL-1β: interleukin-1-beta; IL-
6: interleukin-6; IL-8: interleukin-8; MMP-8: matrix metallo-proteinase-8; NCD: non-
communicable disease; NSPT: non-surgical periodontal disease; PMNs: polymorphonuclear 
neutrophils; RCT: randomised controlled trial; SES: socioeconomic status; SRP: scaling and 
root-planing; TIMP-1: tissue inhibitor metallo-proteinase-1; TNF-α: tumour necrosis factor 
alpha. 
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BACKGROUND 
DESCRIPTION OF THE CONDITION 
Periodontal disease is one of the most common public health concerns worldwide (Tonetti 
2017). It is a chronic inflammatory disease of the periodontium and the most prevalent 
infectious oral condition (Nazir 2017). Although periodontal disease is treatable and can be 
prevented, it is the most frequent cause of tooth loss in adults with about 5 - 15% prevalence 
in most populations (Petersen 2003). The signs and symptoms of periodontitis includes: 
persistent halitosis, red or swollen gingiva, tender/ bleeding gingiva, painful mastication, loose 
teeth and gingival recession. Worldwide, the prevalence of the disease varies in different 
countries, in the United States of America (USA), about 50% of the adult population above 30 
years of age present with some form of periodontitis, ranging from mild to severe periodontitis 
(Eke 2015). According to Kassebaum (2010), severe chronic periodontitis (SCP) was rated 
the 6th most prevalent non-communicable disease (NCD) in the world, affecting 10.8% of the 
population (Uncertainty Interval 10.1% - 11.6%); translating to 743 million people across the 
Globe (Kassebaum 2014). Additionally, prevalence of SCP increases with age, revealing a 
steep increase between the 3rd and 4th decades of life, with a spike in incidence around the 
age of 38. At the age of 40, the prevalence of SCP reaches its peak (Kassebaum 2014). 
The etiology of periodontitis is complex and includes the presence of specific pathogens, 
such as Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans and Prevotella 
intermedia in a susceptible host (Trinidade 2008). Recent systematic reviews and prospective 
studies identified certain potential risk factors which increases the odds of periodontitis. 
Among these are tobacco use (Lorenzo 2015), diabetes (Löe 1993), unhealthy diet 
(Adegboye 2012), genetic factors (Liu 2012), stress (Laforgia 2015) and excessive alcohol 
consumption (Adegboye 2012). Central to the disease process of periodontitis is the 
formation of biofilm on tooth and root surfaces of the tooth which triggers the immune system. 
The inflammatory host response affects the tissues surrounding the teeth, resulting in 
destruction of the periodontal apparatus (Novak 2002). In its advanced stage, periodontitis 
can lead to difficulty in mastication and speech and can adversely affect general well-being 
and quality of life (Johansson 2006). The diagnosis of periodontal disease is based on clinical 
measures of inflammation, such as bleeding on probing, pocket probing depth and 
attachment loss, as well as radiological evidence of bone destruction (Bolerazska 2016). 
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Above all, the effects of periodontitis appear to manifest beyond the local oral tissues, 
affecting the systemic environment (Needleman 2004; O'dowd 2010). Several studies have 
suggested an association between certain NCDs, socioeconomic status (SES), adverse 
pregnancy outcome and periodontal infection (Gomes-Fihlo 2010; Lalla 2011; Tonetti 2013). 
Furthermore, periodontitis has been associated with certain conditions, such as 
cardiovascular disease (Blaizot 2009), diabetes (Hu 2004; Wang 2007; Dehghan 2007; 
Pradhan 2001), respiratory disease (Scannapieco 2003) and systemic inflammatory 
conditions (Nadeem 2009; Lamster 2016). 
Periodontal treatment entails the elimination of biofilm and microbial deposits from the root 
surfaces in order to reduce the inflammatory host response and tissue destruction (Kepic 
1990; Hinrichs 1985). Although there are several treatment approaches for periodontitis, 
conservative mechanical debridement (scaling and root planing [SRP]) has been the most 
common therapy (Matthews 2014). Depending on the severity of inflammation, mechanical 
debridement combined with systemic antibiotic use has been advocated as a treatment 
option. However, there is currently insufficient scientific evidence to support or refute whether 
systemic antibiotics effectively enhances the results of mechanical periodontal treatment 
(Monte-bugnoli 2005; Iwamoto 2003; Heitz-Mayfield 2009; Tüter 2007; Emingil 2011; 
O'Connell 2008). 
The most studied inflammatory biomarkers in relation to periodontitis include: 
1. Matrix Metalloproteinases (MMPs)
2. Tissue Inhibitors of MMPs (TIMPS)
3. Cytokines/Interleukins (IL-1β, IL-6 & IL-8)
4. C-Reactive Protein (CRP)
5. Glycosylated Hemoglobin (HbA1c)
TNF-α is a cytokine, which has been omitted from the review, as it exhibits an early rise and 
fall after an inflammatory stimulus, being an unstable biomarker, with very low basal levels 
that escape most commercial detection assays (D'Aiuto 2013). 
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Matrix Metalloproteinases (MMPs) 
MMPs are a group of proteolytic enzymes that play an important role in the degradation of 
collagen and extracellular matrix in conditions such as osteoarthritis, tumour cell invasion, 
rheumatoid arthritis and autoimmune skin lesions (Birkedal-Hansen 1993). In the periodontal 
disease process, fibroblasts, neutrophils, macrophages, keratinocytes and endothelial cells 
can produce MMPs. MMP-8 is a significant biomarker in periodontitis and also known as 
collagenase-2 or neutrophil collagenase. 
Tissue Inhibitors of MMPs (TIMPs) 
TIMPs are endogenous tissue regulators of MMP activity. A variety of cells produce TIMPs, 
including endothelial cells, fibroblasts, macrophages and keratinocytes (Birkedal-Hansen 
1993). In periodontitis, the TIMPs and MMPs proportion is disturbed/skewed toward higher 
levels of MMPs (Preshaw 2004). TIMPs have an inhibitory effect on MMP-8 and MMP-9, 
enzymes which predominantly destroys type-1 collagen in periodontitis. 
Cytokines 
Cytokines are a group of proteins released in response to an activating stimulus and they 
function through binding to specific cellular receptors (Lagdive 2013), being produced by a 
variety of cells in the human body (Birkedal-Hansen1993). Interleukins are among the 
cytokines that seem to be linked to the inflammatory response seen in chronic periodontitis 
(Takashiba 2003). 
Interleukin-1β (IL-1β) 
IL-1β is responsible for bone resorption and has an inhibitory effect on bone formation. It 
stimulates prostaglandin synthesis and facilitates the up-regulation of inflammatory response 
(Faizuddin 2003). 
Persons with periodontitis have increased IL-1β levels, which can be measured in the GCF as 
well as in the periodontal tissues. The IL-1β functions as a biomarker for periodontal 
destruction. Studies have found a correlation between levels of IL-1β and the severity of 
periodontitis (Masada 1990). 
Stellenbosch University  https://scholar.sun.ac.za
9 
 
Interleukin-6 (IL-6) 
IL-6 is a pro-inflammatory cytokine, which regulates the host response to tissue injury, 
inducing formation of CRP (Dasanayake 2009). Together with IL-1, IL-6 facilitates tissue 
destruction by elevating the MMP levels (Okada 1998). 
IL-6 is produced by monocytes, vascular endothelial cells, osteoblasts and fibroblasts in 
reaction to inflammatory challenges (Haba 2011). They promote immunoglobulin production 
by plasma cells and are co-stimulators of T-cell activation (Scully 2003). In periodontitis, initial 
host response is part of the acute-phase response initiated by the activation of fibroblasts, 
endothelial cells and local macrophages, which lead to the release of the TNF-α, IL-6 and IL-
1β mediators (Qvarnstrom 2010). 
Interleukin-8 (IL-8) 
 
IL-8 is a constituent of the IL-8 supergene family, that is capable of  activating 
polymorphonuclear leukocytes (PMNs) which is the reason why it has also been linked to 
inflammation (Chung 1997). Lagdive (2013) has found that high levels of IL-8 in the GCF of 
adult patients correlated with destruction of the periodontal tissues. 
C-Reactive Protein (CRP) 
CRP is produced by the liver and considered as a biomarker for several conditions, such as 
inflammatory disorders, osteomyelitis, systemic inflammation, neoplasms, vasculitis and 
rheumatoid arthritis (Paraskevas 2008). High sensitivity CRP (hsCRP) can estimate cardiac 
and transient ischaemic attack (TIA) (Paraskevas 2008). Several studies support the finding 
of high levels of serum CRP in patients with periodontitis (Paraskevas 2008). Danisia Haba 
(2011) proposed that the higher levels of CRP in chronic periodontitis patients could make 
them more susceptible to cardiovascular disease. 
Glycated Haemoglobin (HbA1c) 
Diabetes Mellitus is one of the most studied risks factors for periodontal disease. Studies 
have reported that poor glycaemic control is correlated with higher risk for periodontal 
disease (Mealey 2006). It has been suggested that there is a 2-way relationship between 
glycaemic control and periodontal disease (Tervonen 1997). Improvement in glycaemic 
control seems to decrease the risk for periodontitis while periodontal treatment might improve 
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glycaemic levels in type 2 diabetes mellitus patients (Sanchez-Zamora 2014). Glycaemic 
control is rated as one of the most important factors in the prevention of diabetes 
complications. Glycated haemoglobin (HbA1c) is used as an indicator of serum glucose 
levels during the 4-month life-cycle of the red blood cell, thus being a surrogate marker for 
glycaemic control (Higgins 2013). 
Periodontitis treatment regimens 
Periodontal therapy without antibiotics 
There are numerous studies illustrating the positive effects of Scaling and Root planning 
(SRP) alone on systemic biomarkers (Fiorini 2013; Ghodpage 2014; Moeintaghavi 2012; 
Sexton 2011). Good glycaemic control seems to be a pre-requisite for mechanical 
debridement to have a decreasing effect on HbA1c in periodontitis patients with type 2 
diabetes mellitus (Kaur 2015; Dag 2009; Raman 2014; Wei 2011). Several randomised 
clinical trials (RCT) have suggested the efficacy of mechanical debridement in decreasing 
HbA1c levels in blood (Moeintaghavi 2012; Kiran 2005; Zhang 2013; Chen 2012; 
Koromantzos 2012; Li 2011; Faria-Almeida 2006; Artese 2015; Engebretson 2013; Madden 
2008). Regarding MMP-8 levels, a study showed that salivary MMP-8 decreases after 
mechanical debridement (Sexton 2011). A number of studies reported on IL-1β level, the 
efficacy of SRP was documented in the following studies: Sexton 2011 confirmed reduction in 
salivary IL-1β levels; blood/circulating IL-1β levels (Al-Mubarak 2002; Ide 2003) and 
decreased in GCF IL-1β levels (Fiorini 2013). The GCF levels of TIMP-1 have also shown a 
decrease after mechanical debridement (Ghodpage 2014). 
Amongst the RCT’s evaluating IL-6 levels, four studies revealed a decrease in 
circulating/blood IL-6 levels (Artese 2015; Vidal 2009; Tonetti 2007) and GCF IL-6 levels 
(Fiorini 2013) after mechanical debridement. With regards to IL-8, three studies demonstrated 
a decrease in salivary IL-8 levels (Sexton 2011), GCF IL-8 levels (Fiorini 2013) and 
circulating IL-8 levels (Artese 2015). Ten RCTs demonstrated a decrease in blood CRP levels 
after mechanical debridement/SRP alone (Raman 2014; Chen 2012; Koromantzos 2012; 
Vidal 2009; Tonetti 2007; Koppolu 2013; Kamil 2011; Bokhari 2012; Michalowicz 2009; Taylor 
2010). 
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Periodontal therapy with antibiotics  
Currently, evidence suggests that mechanical debridement together with doxycycline 
antibiotics [or sub-antimicrobial-dose doxycycline (SDD)] decreases the HbA1c levels in 
blood biomarkers in type 2 diabetes mellitus (O'Connell 2008; Promsudthi 2005; Tsalikis 
2014; Gaikwad 2013; Gilowski 2012; Botero 2013; Jones 2007; Singh 2008; Rodrigues 2003; 
Yun 2007; Engebretson 2007). 
Concerning TIMP-1, SDD was able to down-regulate gingival crevicular fluid (GCF) levels of 
EMMPRIN, which is an up-regulator of MMP’s, and this was associated with increased TIMP-
1 levels (Emingil 2008). Other reports also suggest that doxycycline associated with non-
surgical periodontal treatment (NSPT) increased GCF TIMP-1 levels (Gorska 2006; Choi 
2004). Lower IL-6 levels have been reported in both GCF (Emingil 2011; Choi 2004) and 
serum (O'Connell 2008; D'Aiuto 2005) after NSPT and antibiotic therapy. GCF MMP-8 levels 
have also shown a reduction in many studies on SRP combined with antibiotics (Tsalikis 
2014; Gilowski 2012; Choi 2004; Lee 2004; Tüter 2010; Emingil 2004). 
Reduced serum CRP and IL-1β levels have also been associated with NSPT combined with 
SDD (D'Aiuto 2005; Koppikar 2013; Lopez 2012; Giannopoulou 2016; Almaghlouth 2014). 
Lastly, salivary IL-8 levels decreased after SRP and antibiotic therapy (Guentsch 2008). 
Antibiotics used in the treatment of periodontitis 
A wide variety of systemic antibiotics have been used in the treatment of periodontitis. The 
most widely used are: Amoxicillin (AM), Azithromycin (AZ), Clarithomycin (CLAR), 
Doxycycline (DOX), Metronidazole (MET), Moxifloxacin (MOX), Ornidazole (ORN) and 
Clavulanate (CLAV). AM combined with MET is the most popular combination in the 
treatment of periodontitis (Garcia Canas 2015). 
Reasons for excluding Aggressive Periodontitis from this review 
Chronic periodontitis is characterized by periodontal tissue destruction which is 
commensurate with local factors, with progression ranging from slow to moderate. However, 
in aggressive periodontitis, there is rapid progression of attachment loss in systemically 
healthy patients. The scale of tissue destruction is disproportionate to the amount of plaque 
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and calculus (Sadeghi 2018). Other reasons for excluding aggressive periodontitis from this 
review include: 
(i) Genetics
Studies have shown that very few subgingival bacterial species differed between chronic and 
aggressive periodontitis patients (Heller 2012), which has led to studies on genetic 
predisposition (Kinane 2001) and familial patterns of disease (Baer 1971; Meng 2011; Rapp 
2010) as potential risk factors for aggressive periodontitis. 
(ii) Local Risk Factors
In aggressive periodontitis, there is a lack of relationship between local etiologic factors and 
the amount of periodontal destruction (Baer 1971). In contrast, in chronic periodontitis, local 
factors play a major role (Albandar 2002). 
(iii) Rate of Bone Loss
In aggressive periodontitis, the rate of bone loss has been described as 3-4 times higher than 
the rate of progression of chronic periodontitis (Baer 1971; Schatzle 2003). 
Lastly, aggressive periodontitis and chronic periodontitis share common disease 
manifestations and outcomes since they are likely to represent two distinct disease 
categories with differences with regards to disease progression, underlying causes and risk 
factors. 
(iv) Hyper-responsive phenotype
Aggressive periodontitis requires systemic diseases to be excluded for its diagnosis 
(Moharamzadeh 2018) to be established. Since our study population consisted of patients 
with co-morbidity, Trials that on aggressive periodontitis were excluded. 
In aggressive periodontitis, the macrophage phenotype is hyper-responsive, together with 
elevated prostaglandin (PG)E2, and Interleukin (IL)-1β in response to bacterial endotoxins (Lu 
1994). The hyper-responsive in aggressive periodontitis would likely cause a spike in the IL-
1β levels, which could lead to very high base-line levels of IL-1β which could confound the 
treatment effects thereby producing a bias in the study. Thus, trials on aggressive 
periodontitis were excluded from the study.  
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(v) Actinobacillus Actinomycetemcomitans (AA)
The levels of Actinobacillus Actinomycetemcomitans (AA) are significantly elevated in 
aggressive periodontitis patients (Asikainen 1991). Our treatment modalities consisted 
primarily of non-surgical periodontal therapy (NSPT) with antibiotics as an adjunct. In the 
case of aggressive periodontitis, NSPT and surgical periodontal therapy are not sufficient for 
the elimination of AA in localized aggressive periodontitis (Moharamzadeh 2018).  AA 
invades the soft tissues and produces leucotoxins, immunosuppressive factors and 
collagenase (MMPs) (Könönen 2014). Here again, we anticipated conducting a meta-analysis 
on the MMP-8 biomarker subgroup. However, due to the elevated AA’s in aggressive 
periodontitis which would not subside even in spite of NSPT, this would lead to elevated 
baseline levels of MMP-8 in the aggressive periodontitis patients and once pooled with MMP-
8 from chronic periodontitis patients, we would not be able to ascertain the true effect of 
antibiotics combined with SRP on aggressive nor chronic periodontitis patients.  
Studies evaluating local antibiotics 
Studies assessing the effects of local antibiotics on periodontitis will not be included the 
review. Several reviews on local antibiotics in the form of antimicrobial irrigants (Magnusson 
1998; Nagarakanti 2015; Gjermo 1993), chlorhexidine chips (Cosyn 2006) and subgingival 
chlorhexidine gel (Cosyn 2005) has shown less effective results. Magnusson (1998) reported 
little long-term efficacy of antimicrobial irrigants, while Cosyn (2006) reported limited and 
conflicting results. Nagarakanti (2015) stated that evidence was insufficient regarding 
potential benefits of subgingival irrigation. Gjermo (1993) reported that subgingival 
antibacterial agents have no effects on periodontitis. In their review (Cosyn 2005), it was 
concluded that subgingival chlorhexidine gel administration was not a justified treatment. In 
contrast, a review (Jepsen 2000) showed additional pocket depth reduction and attachment 
gain associated with local antimicrobials. Hussein (2007) also reported improved clinical 
outcomes with the use of locally delivered antibiotics. Since most of the studies have not 
been able to confirm the efficacy of local antimicrobials in the treatment of periodontitis, their 
application has been excluded from the current review. Moreover, Mombelli (2012) has stated 
that amoxicillin and metronidazole when systemically administered is a superior form of 
treatment and no other regime has shown superiority in the treatment of periodontal disease. 
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DESCRIPTION OF THE INTERVENTION 
Previous meta-analyses (Herrera 2002; Drisko 1996; Winkelhoff 1996) and systematic 
reviews (Elter 1997; Moreno Villagrana 2012; Hayes 1992) have looked at the benefits of 
antimicrobial agents in providing systemic clinical benefit. Another study suggested that 
systemic antibiotic therapy is effective in reaching micro-organisms, which are otherwise 
inaccessible to scaling instruments and local antibiotic therapy (Bidault 2007). SRP alone 
(without adjunctive antibiotics) has been shown to reduce the risk for cardiovascular disease 
(CVD) and diabetes mellitus by improving plasma levels of inflammatory (CRP, IL-6, TNF-α) 
and metabolic (HbA1c) markers of endothelial function (Teeuw 2014). 
HOW THE INTERVENTION MIGHT WORK 
Several molecules have been identified as potential biomarkers for periodontal disease, 
including proteins, cytokines, receptors and enzymes. These biomarkers have been identified 
and measured in the gingival crevicular fluid (GCF), which provide information on the local 
periodontal destruction, in serum and saliva. In saliva, high levels of matrix metallo-
proteinases (MMPs, including MMP-8, MMP-14 and TIMP-1) have been associated with 
periodontitis (Sorsa 2004). Marcaccini (2010) reported that salivary MMP-8 and MMP-9 can 
be used as indicators of periodontal treatment response. Systemically, serum or blood 
biomarkers have been associated with periodontal disease. The level of C-reactive protein 
(hs-CRP) and inflammatory cytokines in serum have been linked to periodontitis (Nakajima 
2010). Periodontitis leads to the production of local inflammatory mediators, which have the 
potential to enter the systemic circulation, thus causing an inflammatory burden (Susanto 
2012). An increase in the serum C-reactive protein (CRP) levels is indicative of the 
inflammatory burden, as seen in periodontitis patients (Noack 2001; Craig 2003; D'Aiuto 
2004; Salzberg 2006; Linden 2008; Pitiphat 2008). Simultaneously, bacteria and their 
products can enter the systemic circulation causing an infectious burden (Susanto 2012). 
Circulating oral bacteria stimulate hepatocytes to secrete CRP (Mealey 2006; Li 2000; Soell 
2007). Increased levels of CRP associated with periodontitis result in insulin resistance and 
subsequent impaired control of blood glucose in type 2 diabetes mellitus (DM2) (Hu 2004; 
Wang 2007; Dehghan 2007; Pradhan 2001), which in turn increases the levels of HbA1c 
(Taylor 1999; Nesse 2009). 
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WHY IT IS IMPORTANT TO DO THIS REVIEW 
Mechanical debridement combined with proper oral hygiene measures can reduce or prevent 
further periodontal damage in individuals with periodontitis. Several studies have suggested 
that combining antibiotics with mechanical debridement and oral hygiene (SRP) could reduce 
periodontal disease drastically. The effects of antibiotic combined with mechanical 
debridement on blood biomarkers, however, needs to be established. Diabetes mellitus and 
cardiovascular diseases are among the systemic diseases that have huge economic burden 
worldwide. Periodontal treatment has been shown to reduce glycemia and lower HbA1c 
levels in diabetic patients (Dag 2009; Botero 2013; Jones 2007; Wang 2014; Javed 2014). 
Meta-analyses also support a positive effect of periodontal treatment on glycemic control (Li 
2015; Liew 2013). 
The potential economic benefit of periodontal therapy on glycemic control can have a 
significant impact in terms of health care costs. Brod (2016) pointed out that the annual costs 
per person for missed work-time due to post-prandial hyperglycemia (PPH) was considerable 
and estimated it at €394.78 in Germany (given €8.48 per week; 40 work weeks), £396.83 in 
the UK (given £8.62 per week; 46 work weeks) and U$606.30 in the USA (given U$13.05 per 
week; 47 work weeks). 
With regards to cardiovascular diseases (CVD), periodontal therapy has been shown to 
reduce the risk for CVD by improving plasma levels of inflammatory, thrombotic and 
metabolic markers (Tüter 2007; Teeuw 2014; Koppolu 2013; Bokhari 2012) and changing the 
systolic blood pressure (D'Aiuto 2006). In addition, periodontal therapy normalized 
haematological markers levels in CVD sufferers (Taylor 2010) and reduced low grade 
systemic inflammatory markers and lipid profile (Caúla 2014). Researchers have reported 
that the direct costs of CVD were a cumulative U$272 Billion for the USA (Laslett 2012), with 
an annual estimate of €106 Billion for the European Union (Eur Heart Network). A plethora of 
studies has declared the benefits of periodontal therapy on the reduction of CRP levels, 
which is directly related to cardiovascular health. These findings, if proven to be conclusive, 
can translate into a substantial reduction in the economic burden of diabetes and CVD.  
OBJECTIVES 
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To conduct a systematic review of the effectiveness of systemic antibiotics as an adjunctive 
therapy to mechanical treatment in the improvement of inflammatory systemic biomarkers as 
compared to mechanical debridement alone in chronic periodontitis. The study will be a 
systematic review and not a RCT. 
METHODS 
CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW 
TYPES OF STUDIES 
All randomised controlled trials (RCTs) where the use of systemic antibiotics combined with 
mechanical debridement versus mechanical debridement alone or with placebo were 
included. 
TYPES OF PARTICIPANTS 
Studies with participants diagnosed with chronic periodontal disease were included. Studies 
with participants having co-morbidity such as diabetes mellitus, cardiovascular diseases, 
chronic obstructive pulmonary disease or chronic kidney disease (minimum 18 years and 
above), and chronic periodontitis were also included. 
Apoptosis is a process which involves morphological and biochemical events in the cell 
resulting in its death and its elimination by phagocytes (Cohen 1991). Neutrophils from 
individuals with both diabetes and chronic periodontitis displayed a significant decrease in 
apoptosis as compared to people with diabetes or chronic periodontitis alone. Caspases 
are cytosolic proteases which bring about the apoptotic morphology in a cell and their 
presence is a hallmark of apoptosis activation (Gammonal 2001). The caspase-3 activities 
were also reduced drastically in these systemically compromised individuals as compared to 
healthy individuals with chronic periodontitis (Hasturk & Kantarci 2015). Increased caspase 
activation has been detected in inflamed gingival biopsies while no caspase activation was 
observed in healthy tissue (Bantel 2005). This finding implies that periodontitis-associated 
tissue damage involves caspase activation. An example on the therapeutic value of 
antibiotics is that of azithromycin which reduces the expression of Toll-like receptors (TLR), 
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TLR-2 (Karlström 2011) and TLR-4 (Maezono 2011, Iwamoto 2011), thereby promoting the 
recruitment of neutrophils which TLR-2 and TLR-4 seek to inhibit. 
 Azithromycin improves the phagocytosis of apoptotic neutrophils (Hodge 2006). Once the 
polymorphonuclear leukocytes (PMNs) are infiltrated by azithromycin, the release of 
azithromycin is very slow. This sustained retention of azithromycin by PMNs facilitates 
delivery and release of the drug at the site of infection (Hand 2001). Azithromycin also 
reduces PMN chemotaxis and induces PMN apoptosis. 
Severe inflammation resulting in local tissue destruction occurs when neutrophil apoptosis is 
inhibited (Stockley 2006). Decreased levels of IL-1β, IL-8, TNF-α and MMP-8 have also been 
observed following azithromycin administration in chronic and aggressive periodontitis (Ho 
2010, Lai 2011, Han 2012, Emingil 2012). It therefore clear that there is a difference in the 
host response to antibiotics in a healthy individual compared to an individual with a co-
morbidity during periodontal treatment. Therefore the results from this review should be 
interpreted with caution. 
The immune responses in different individuals has been noted and has been discussed 
above. Currently, the association between chronic periodontitis (CP) and non-communicable 
disease (NCDs) is a relatively recent development and of global interest (Global Burden of 
disease), thus, we have flagged the need to interpret the results with caution as immune 
responses between healthy individuals and sick individuals could vary substantially. 
TYPES OF INTERVENTIONS 
All interventions that included mechanical debridement combined with adjunctive systemic 
antibiotics for the treatment of chronic periodontitis were considered for inclusion. 
Chronic periodontitis is defined as an infectious oral disease leading to an inflammatory 
response within the supporting tissues of the teeth, resulting in progressive attachment and 
alveolar bone loss (Flemming 1999). The clinical features include- colour, texture and volume 
alterations of marginal gingivae, periodontal pocket formation, bleeding on probing (BOP), 
bone loss, furcation exposure and drifting and exfoliation of teeth (Moharamzadeh 2018). 
ACAL/PD>4 mm with or without BOP in chronic periodontitis (Mdala 2014) while periodontal 
pockets equal to or greater than 6 mm in advanced stages (WHO 2005).
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Prior to 2018, The American Academy of Periodontology (AAP) classified periodontal disease 
into into 8 main groups: - Gingival diseases, 3 types of periodontitis (chronic, aggressive and 
manifestation of systemic diseases),and four additional periodontal conditions which include: 
necrotizing periodontal diseases, abscesses in the periodontium, periodontitis associated with 
endodontic lesions and acquired or developmental deformities and conditions (Armitage 
1999). A new classification based on stage and risk of disease progression was proposed in 
March 2018. The new classification includes a sound medical and dental history taking and 
detailed clinical assessment to identify cases of periodontal disease. The steps and 
procedure for periodontal disease diagnosis includes: 
• Medical history and risk factors, e.g. diabetes, smoking, hypertension, medications,
substance abuse, HIV/AIDS, pregnancy, or other existing conditions that may affect
treatments
• Dental history including the chief complaint(s)
• Extra-oral examination
• Intra-oral examination
• Teeth examination including occlusal aspects and pulpal status
• Radiographic examination
• Periodontal examination, including presence and distribution of plaque and calculus,
assessment of periodontal and peri-implant soft tissues, and measurement of probing
depth, gingival recession (or enlargement) and bleeding on probing at six sites per
tooth. Furcation lesions and mucogingival aspects should be carefully explored (FDI).
Other important indicators such as genetic conditions, microbiologicaland host biomarkers 
could also aid clinical diagnosis (Armitage 2013).
New Classification of Periodontitis 
Very recently, the 2017 World Workshop Classification System for periodontal and peri-
implant diseases was developed (Dietrich 2018). 
In the 2017 classification system, the demarcation between chronic and aggressive 
periodontitis was removed due to there being insufficient evidence from biological studies that 
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chronic and aggressive periodontitis were separate conditions. They were seen to be merely 
variations of the same disease process. 
Necrotising Periodontitis and Periodontitis as a manifestation of systemic disease are the only 
other forms of periodontitis recognized by the 2017 classification system (Papapanou 2018). 
Upon being diagnosed as having periodontitis, Staging and Grading are performed as per the 
criterion set-out by the 2017 classification system. 
The basic classification of the 2017 World Workshop on Periodontal Diseases are as follows 
in 3 broad sections, namely: 
Periodontal health, gingival diseases and conditions: 
Periodontal health (comprising of either: intact periodontium OR, reduced periodontium) 
Gingivitis: dental biofilm-induced (comprising of either:  of intact periodontium OR, reduced 
periodontium) 
Gingival diseases and conditions: non-dental biofilm-induced 
Periodontitis (comprising of either: Necrotising periodontal diseases OR, Periodontitis OR, 
Periodontitis as a manifestation of systemic disease). 
Other conditions affecting the periodontium (comprising of either Systemic diseases or 
conditions affecting the periodontal supporting tissues, OR, Periodontal abscess and 
endodontic-periodontal lesions, OR Mucogingival deformities and conditions, OR, Traumatic 
occlusal forces, OR, Tooth and prosthesis and related factors). 
TYPES OF OUTCOME MEASURES 
PRIMARY OUTCOMES 
• Changes in serum/blood levels of inflammatory biomarkers such as:
1. MMPs
2. TIMPs
3. Cytokines
4. CRP
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5. Glycated haemoglobin (HbA1c) 
 
SECONDARY OUTCOMES 
• Gingival index 
• Plaque index 
• Pocket depth and  
• gingival recession 
 
SEARCH METHODS FOR IDENTIFICATION OF STUDIES 
To identify studies for this review, we adopted the following search terms and strategy: "anti-
bacterial agents” [medical subject headings {MeSH}] OR "anti-infective" OR “systemic 
antibiotics” OR “antibiotic OR "antibiotic therapy”) AND (periodontitis OR “chronic 
periodontitis” OR “periodontal diseases” [MeSH] OR “periodontitis” [MeSH]. The search terms 
and strategies were used to identify relevant trials in MEDLINE database. The same method 
was appropriately used for each of the other relevant databases searched.  
Electronic database search was combined with hand search to identify trials for inclusion in 
the review. Attempts were also made to identify unpublished and grey literature. RCTs 
published from 1980 to May 2018 were considered for inclusion. See appendix 1 for used 
search terms. 
 
ELECTRONIC SEARCHES 
The following databases were searched for relevant trials: 
Cochrane Oral Health Group’s Trials Register 
CENTRAL – Cochrane Register of Controlled Trials (of the Cochrane Library – current issue) 
MEDLINE (1966 to present) 
EMBASE (1982 to present) 
CINAHL (1990 -present) 
Google scholar (1990 - present) 
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ONGOING TRIALS DATABASES 
We searched the following on-going trials registers (02/06/2018) to identify relevant trials 
using the term 'periodontal disease' and 'systemic antibiotics' OR antimicrobial OR 
'mechanical debridement'. 
The metaRegister of Controlled Trials (www.controlled-trials.com) The US National Institutes 
of Health On-going Trials Register (www.clinicaltrials.gov). The World Health Organization 
International Clinical Trials Registry platform (www.who.int/trialsearch) 
SEARCHING OTHER RESOURCES 
Reference lists and Correspondence: We searched reference lists of all included studies 
and reviewed articles for relevant trials. (21/09/2018) 
We also contacted authors of included studies and experts in the field of oral health care to 
identify any additional published or unpublished trials. (16/08/2018). 
We also searched the ProQuest database, Stellenbosch University database and Google 
scholar (10/08/2018). See Appendix 1 for search terms. 
HAND SEARCHING 
Trials published prior to 1991 were hand searched since no indexing terms for randomized 
trials in MEDLINE existed (Lefebvre 2009). All trials in parts of journals (supplements and 
conference abstracts) which were not routinely indexed in databases such as MEDLINE were 
hand searched. We did not apply any date or language restrictions. 
DATA COLLECTION AND ANALYSIS 
SELECTION OF STUDIES 
Two review authors, Sudhir Munasur (SM) and Eunice Turawa (ET) independently screened 
the titles and abstracts of the search output to identify and select potentially eligible studies 
[Figure1]. Applying eligibility criteria using a pre-designed eligibility form based on the 
inclusion criteria, duplicate studies and studies that were not relevant to the review were 
excluded. Full-text articles of potentially relevant studies were retrieved, and disagreements 
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were resolved through discussion or, if required, a third author would add his input to enable 
a consensus on such review (Usuf Chikte (UMEC)). The reference lists for the included 
studies were screened for additional studies. 
DATA EXTRACTION AND MANAGEMENT 
Data extraction form was designed for extraction of relevant information. For eligible studies, 
two review authors (SM and ET) extracted the data using the data extraction form. The 
following data were extracted from each study: 
- Authors, trial-year, country of study, funding, whether university based or not.
- Specific trial characteristics: the type of study population, age, gender, periodontal disease
diagnosis and severity, number of participants recruited and number of participants
completing the trial, withdrawals and the reasons thereof, overall sample size.
- Primary and secondary outcomes. In case of missing data, the authors of the reports were
contacted. For each outcome, we extracted the arithmetic mean and standard deviation (or
information to estimate the standard deviation). We resolved discrepancies through
discussion or, if required, we consulted the third author (UMEC). We checked for accuracy
and when information regarding any of the above is unclear, we contacted authors of the
original reports to provide further details.
STUDY QUALITY ASSESSMENT 
Two review authors (SM and ET) independently and in duplicate performed a quality 
assessment of the included studies. All trials that met the inclusion criteria were assessed on 
four major criteria: randomization method, concealment of allocation, blinding of patients and 
care providers, and accurate description of withdrawals and drop outs. 
Any disagreements between the review authors were resolved by consensus. Quality, 
criteria, the definition thereof was based on guidelines from the Cochrane Handbook for 
Systematic Reviews of Interventions. 
ASSESSMENT OF RISK OF BIAS IN INCLUDED STUDIES 
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Risk of bias for each study was assessed independently by the 2 review authors (SM and ET) 
using the criteria outlined in The Cochrane Handbook for Systematic Reviews of Interventions 
(Higgins 2008). The method used for allocation sequence generation, the completeness of 
the outcome report, selective reporting and any other source of bias that can put a study at 
high risk of bias were assessed (Appendix 2). Any disagreements were resolved by 
discussion or by consulting a 3rd assessor. 
MEASURES OF TREATMENT EFFECT 
Mean Difference (MD), with its corresponding 95% confidence interval (CI), was used as the 
effect size for continuous data that were measured using the same scale (for instance, pocket 
depth (mm)). There were no cases where continuous data were measured using different 
scales of measurement, in which case the Standardized Mean Difference (SMD) would have 
been used. For binary data, use of the risk ratio (RR) was anticipated with its corresponding 
95%CIs; however, included studies did not report the necessary raw data to calculate these 
and in most cases odds ratios (OR) were reported or p-values according to the study authors. 
In other instances, the significance of the differences between the treatment-arms was 
reported according to the study authors as there were no relevant data to calculate treatment 
effects. 
UNIT OF ANALYSIS ISSUES 
Cluster randomized trials were not included in this systematic review and therefore there was 
no need to adjust analyses for clustering. There were four studies where there were more 
than two treatment arms, however, there were no meta-analysis data that needed choosing 
two treatment arms for analysis to avoid double counting the participants from the same 
control arm. 
DEALING WITH MISSING DATA 
Study authors were contacted to recover missing data on either outcomes or risk of bias 
though we did not receive any responses. Levels of attrition were noted in the included 
studies and assessed under risk of bias section. For each outcome in each trial, the 
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denominator was calculated using the number of randomized subjects minus any participants 
whose outcomes were missing. 
ASSESSMENT OF HETEROGENEITY 
Heterogeneity was assessed using the Chi-squared-based Q-statistic method (using p<0.1 to 
indicate statistical significance due to the low statistical power of this particular test) and the I2 
measurement (where values 50% or higher indicated significant heterogeneity). 
ASSESSMENT OF REPORTING BIASES 
We had intended to assess the likelihood of publication bias by assessing the asymmetry of 
funnel plots, however, this could not be done due to insufficient number of studies in our 
meta-analyses. 
DATA SYNTHESIS 
We performed random effects meta-analysis using RevMan 5.3 software for some continuous 
secondary outcomes. Results were reported as mean differences with appropriate 95% CI 
and displayed using forest plots. Due to insufficient data, many outcomes could not be meta-
analysed, and we took the narrative approach in reporting the results. 
SUBGROUP ANALYSIS AND INVESTIGATION OF HETEROGENEITY 
We had intended to identify potential sources of heterogeneity through subgroup analysis 
with respect to the following patient characteristics (self-reported smoking status, initial 
pocket probing depth, immunological disease (HIV), patient adhered plaque control) or 
treatment characteristics (class of antibiotics, baseline and follow-up time, number of 
sessions for debridement, supportive follow-up care). Due to insufficient data we could not 
perform these subgroup analyses 
SENSITIVITY ANALYSIS 
Also due to insufficient data, no sensitivity analyses were performed. 
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RESULTS
DESCRIPTION OF STUDIES 
RESULTS OF THE SEARCH 
After de-duplication of identified relevant trials in the EndNote reference, electronic search 
yielded 602 references. These 602 title and abstracts were screened independently and in 
duplicate by two review authors (ET and SM), and 58 records were retained for further 
assessment. The full-text articles of these 58 trials were retrieved and screened for eligibility. 
A total of 42 trials were excluded with reasons (See table of characteristics of excluded 
studies). We finally included 16 trials in this review (Almaghlouth 2013; Botero 2013; 
Engebretson 2011; Gaikwad 2010; Gilowski 2012; Golub-Lee 2008; Grossi 1997; Han 2012; 
Jones 2007; Lopez 2011; Miranda 2014; O’Connell 2008; Payne 2011; Reinhardt 2010; 
Saleh 2016 and Tüter 2007), (See figure 1 and table of characteristics of included studies). 
We reported on 14 trial results considering that three results (Golub-Lee 2008; Payne-Golub 
2011; Reinhardt 2010) were from the same trial but reported differently by the authors, we 
therefore reported the three trials as one. Figure1 shows the study selection process. 
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FIGURE 1: FLOW DIAGRAM OF STUDY SEARCH 
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INCLUDED STUDIES 
A total of 16 randomised controlled trials were identified and assessed for inclusion in this 
review (Almaghlouth 2013; Botero 2013; Engebretson 2011; Gaikwad 2010; Gilowski 2012; 
Golub, Lee 2008; Grossi 1997; Han 2012; Jones 2007; Lopez 2011; Miranda 2014; O’Connell 
2008; Payne 2011; Reinhardt 2010; Saleh 2016 and Tüter 2007). Three reports originated 
from the same trial (Golub,Lee 2008;Payne 2011 and Reinhardt 2010). All included trials 
assessed and compared the effect of antibiotics versus placebo or no antibiotic, with 
mechanical debridement in either arm. 
STUDY SETTING 
Five of the included trials were conducted in developed countries. Three trials were 
conducted in the USA: Engebretson 2011, Grossi 1997, and Jones 2007. The trial by Saleh 
2016 was conducted in Australia, while Almaghlouth 2013 was conducted in Switzerland. 
Two trials Han 2012 and Tüter 2007 were conducted in Turkey; while trials by Miranda 2014 
and O’Connell 2008 were conducted in Brazil. The trial by Lopez 2011 was from Chile, and 
the trial by Botero 2013 was conducted in Coloumbia. Trials by Gaikwad 2010 and Gilowski 
2012 were conducted in India and Poland respectively. All trials were conducted in an 
academic hospital, one study was a multicentre study (Jones 2007) while others were 
conducted in a single centre. 
CHARACTERISTICS OF THE PARTICIPANTS 
In total, 1457 participants (14 trials) were included in the analysis for this review. Participants 
were all diagnosed with moderate-to-advanced chronic periodontitis. The age of the 
participants spanned between 18-70 years old. Seven trials (Botero 2013; Engebretson 2011; 
Gaikwad 2010; Gilowski 2012; Grossi 1997; Jones 2007 and O’Connell 2008) included 
participants with hyperglycaemia (Diabetes); one trial (Tuter 2007) recruited participants with 
coronary artery disease (CAD), while Lopez 2011 included participants with metabolic 
syndrome (MetS). Three trials (Almaghlouth 2013; Han 2012; and Saleh 2016) included 
adults with chronic periodontal disease and Golub-Lee 2008 comprised of participants with 
osteopenic menopausal women (See characteristics of included table). 
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CHARACTERISTICS OF INTERVENTIONS AND COMPARISONS 
All included trials assessed the effect of antibiotics compared with placebo or no antibiotic 
with mechanical debridement in either arms (See Table of characteristics of included studies). 
The intervention groups had broad spectrum antibiotics as an adjunct to the non-surgical 
therapies received. Combination of interventions varied across included trials (See Table 4 
for details). 
Two trials (Botero 2013 and Han 2010) evaluated the effect of Azithromycin 500mg in the 
treatment group compared to placebo in the control group. About 53% of the trials 
(Engebretson 2011; Gaikwad 2010; Jones 2007; Gilowski 2012; Golub-Lee 2008; Grossi 
1997; O’Connell 2008 and Tüter 2007) examined the effects of doxycycline in the test group 
(TG), while the control group (CG) received varied therapy ranging from no treatment to 
placebo.  
Lopez 2011, Miranda 2014 and Almaghlouth 2013 assessed the effect of Metronidazole 
250mg, 400mg and 500mg respectively along with Amoxicillin 500mg, except for Almaghlouth 
2013 which was Amoxicillin 375mg.  Lopez 2011 and Miranda 2014 used placebo for the 
control group while the control group in Almaghlouth 2013 had Chlorhexidine mouth-rinse. 
Saleh 2016 is a three-arm trial, the first group received Metronidzole 200mg with Amoxicillin 
500mg three times daily for 7 days while the second arm had scaling and root planing (SRP) 
followed by Azithromycin 500mg three times daily for 7 days. The last arm (Control group) 
received placebo for 7 days. 
 
OUTCOMES 
PRIMARY OUTCOMES 
Almaghlouth (2013) reported on the following biomarkers: IL-1β, IL-6, IL-8, and CRP, while 
Gilowski 2012 recorded changes in MMP-8 and HbA1c level. Gaikwad 2013, Jones 2007, 
Botero 2013, Engebretson 2011, Grossi 1997 and Miranda 2014 measured the changes in 
HbA1c levels. Golub-Lee 2008 and Han 2012 reported on MMP-8 while Lopez 2011 
estimated CRP serum level and Tüter 2007 quantified the levels of CRP and MMP-8. 
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O’Connell (2008) assessed and reported on IL-1β and HbA1c serum level. As mentioned 
earlier, the studies Golub-Lee 2008, Reinhardt 2010 and Payne,Golub2011 are based on the 
same experimental population and assignment arms (one trial). Golub-Lee 2008 gave a 
detailed report on the trial; hence it was our study under consideration; He measured IL-1β 
and MMP-8 while Reinhardt 2010 gave estimates on IL-1β and MMP-8. Payne,Golub 2011 
reported on level of IL-1β, IL-6, CRP, MMP-8 and TIMP-1.  
SECONDARY OUTCOMES 
Almaghlouth (2013) reported on probing pocket depth/probing depth (PD) in mm. 
Engebretson (2011) estimated PD, clinical attachment loss (CAL) and percentage sites with 
plaque at baseline only. There was no data was found for 3 or 6 months post-baseline. Six 
trials, (Gaikwad 2010; Gilowski 2012; Grossi 1997; Lopez 2017; Miranda 2012; O’Connell 
2008) measured CAL and PD. However, most of the results were portrayed in figures only 
and they could not be extracted accurately for further analysis. 
Jones (2007) reported periodontal pocket depth (sites in percentage) but the data from 
baseline to 4 months was incomplete therefore the data could not be used. Han (2012) 
measured PD sites (percentage), however the data from baseline to 4 months was missing. 
Botero (2013) and Saleh (2016) measured pocket probing depth (PPD), CAL and plaque 
index (PI) while Tüter 2007 reported on PD, CAL and PI. 
Golub-Lee (2008) did not measure any secondary outcomes while Reinhardt (2010) reported 
no baseline values for relative clinical attachment loss (rCAL), and (Payne,Golub 2011) did 
not report any secondary outcomes. 
EXCLUDED STUDIES 
After scrutinizing the full-text papers, 42 trials were excluded from further analysis with 
reasons. The trials did not meet the pre-specified criteria in the protocol. The reasons for 
exclusion are detailed in the Characteristics of excluded studies tables.  
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RISK OF BIAS IN INCLUDED STUDIES 
Two authors independently assessed risk of bias in each of the included trials. The 
assessments were made in accordance with chapter 8 (pp 187 – 241): “Assessing risk of bias 
in included studies” of the Cochrane Handbook for Systematic Reviews of Interventions, 1st 
Edition (Higgins 2008). The judgments regarding the risk of bias in each of the included 
studies were reported in the “Characteristics of included studies”. Summary tables of risk of 
bias in all trials are also displayed in Figure 2 and Figure 3. 
One trial was judged to be at high risk of bias (Jones 2007). Four trials were judged to be at 
low risk of bias (Lopez 2007; Miranda 2011; Saleh 2016; Reinhardt 2010) while Eleven trials 
(Botero 2011; Engebretson 2011; Gaikwad 2010; Gilowski 2012; Golub-Lee 2008; Grossi 
1997; O’Connell 2008; Payne,Golub 2011; Tüter 2007; Almaghlouth 2011; Han 2004) were 
judged as unclear of risk of bias. The available information from these trials was vague and 
insufficient to enable us to judge whether they are at “low risk or high risk of bias”. The 
authors were contacted through series of emails for more information on the trials, but we did 
not receive response from them. Risk of bias table was completed for each of the included 
trials (Characteristics of included studies table; Figure 2 and Figure 3) 
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Figure 2: RISK OF BIAS SUMMARY 
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FIGURE 3: RISK OF BIAS GRAPH 
 
ALLOCATION (SELECTION BIAS) 
Trials were judged for selection bias based on adequate random sequence generation and 
allocation concealment. Eleven trials (Almaghlouth 2013; Botero 2013; Engebretson 2011; 
Gilowski 2012; Han 2012; Jones 2007; Lopez 2011; Miranda 2014; Payne 2011; Reinhardt 
2010; Saleh 2016) reported adequate sequence generation, thus were judged as low risk of 
selection bias in terms of random sequence generation. Ten trials (Almaghlouth 2013; Botero 
2013; Engebretson 2011; Gilowski 2012; Han 2012; Jones 2007; Lopez 2011; Miranda 2014; 
Reinhardt 2010; Saleh 2016) reported adequate allocation concealment and were judged as 
having low risk of selection bias in terms of allocation concealment. Five trials were judged to 
be at unclear risk of selection bias in terms of random sequence generation (Golub-Lee 2008; 
Grossi 1997; O’Connell 2008; Gaikwad 2010; Tüter 2007) on account of insufficient 
information on allocation concealment while six trials were judged to be at unclear risk of 
selection bias in terms of allocation concealment (Payne,Golub2011; Gaikwad 2010; Golub-
Lee 2008; Grossi 1997; O’Connell 2008; Tüter 2007). 
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
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BLINDING (PERFORMANCE BIAS AND DETECTION BIAS) 
Trials were judged for performance bias based on adequate blinding of participants, 
personnel and blinding of outcome assessors. 
The study by Jones (2007) was judged to be at high risk of performance bias in terms of 
blinding of participants and personnel, because the participants, dentist, dental technician 
and assistant were not masked. Nine trials (Almaghlouth 2013; Botero 2013; Gilowski 2012; 
Golub-Lee 2008; Han 2012; Miranda 2014; Reinhardt 2010; Saleh 2016; Tüter 2017) were 
assessed to be at low risk of performance bias in terms of blinding of participants and 
personnel. Lopez (2011) was judged to be unclear of risk of performance bias, only the 
participants were masked. The dentist, dental assistant and dental technician were not 
masked. Five studies (Engebretson 2011; O’Connell 2008; Gaikwad 2010; Grossi 1997; 
Payne,Golub 2011) were judged to be at unclear risk of performance bias in terms of blinding 
of participants and personnel due to insufficient information. Several attempts to contact the 
authors of the trials for more information were unsuccessful. 
Eight trials (Grossi 1997; Han 2012; Jones 2007; Lopez 2011; Miranda 2014; Payne,Golub 
2011; Saleh 2016; Botero 2013) were judged to be at low risk of detection bias in terms of 
blinding of outcome assessment. Gilowski (2012) was judged to be at high risk since the 
statisticians and data committee saw the unblinded data. The remaining seven trials 
(Almaghlouth 2013; Engebretson 2011; Gaikwad 2010; Golub-Lee 2008; O’Connell 2008; 
Reinhardt 2010; Tüter 2007) were judged to be unclearof detection bias in terms of blinding of 
outcome assessment. They were also judged as “unclear” of risk of bias for the following 
reasons: Almaghlouth (2013) and Engebretson (2011) did not report whether the assessor 
was masked or not. Gaikwad (2010) did not report details on masking of the personnel. 
Golub-Lee (2008) did not report whether the assessor was masked or not. O’Connell (2008) 
did not mention if the operator was blinded or not. Reinhardt (2010) did not report on whether 
the assessor was masked or not. Tüter (2007) also did not report whether the assessor was 
masked or not. 
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INCOMPLETE OUTCOME DATA (ATTRITION BIAS) 
Trials were assessed for attrition bias based on incomplete outcome data. 
Eleven trials (Almaghlouth 2013; Botero 2013; Golub-Lee 2008; Grossi 1997; Lopez 2011; 
Miranda 2014; Payne,Golub 2011; Saleh 2016; Tüter 2007; Gaikwad 2010; Reinhardt 2010) 
were judged to be at low risk of attrition bias in terms of incomplete outcome data. Three trials 
(Han 2012; Jones 2007; Engebretson 2011) were judged to be at high risk of attrition bias for 
the following reasons: Han (2012) excluded 22% of the participants and reasons for exclusion 
were not provided. Jones (2007) had 32% of participants not completing the study, we were 
not sure whether the reasons forthe drop-out were related to adverse effects of the 
intervention or not. Engebretson (2011) had a 24% withdrawal and loss to follow-up. The 
reasons and the arm of intervention with the loss to follow up were not reported. Two trials 
(Gilowski 2012; O’Connell 2008) were judged to be unclear risk of attrition bias due to 
inadequate information on follow up. The authors were contacted through series of emails for 
the missing data, but there was no response from them. 
SELECTIVE REPORTING (REPORTING BIAS) 
Included trials were assessed for selective reporting. The following four trials (Golub-Lee 
2008; Miranda 2014; Saleh 2016; Tüter 2007) were judged to be at low risk of selective 
reporting bias. Three trials (Almaghlouth 2013; Botero 2013; O’Connell 2008) were judged to 
be at high risk of selective reporting bias due to the following reasons: Almaghlouth (2013) 
did not make a distinction between patients receiving antibiotics or placebo. Botero (2013) did 
not report the value that was calculated between the two treatment groups. O’Connell (2008) 
did not provide separate data/results for the intervention group and placebo group. Nine trials 
(Engebretson 2011; Gaikwad 2010; Gilowski 2012; Grossi 1997; Han 2012; Jones 2007; 
Lopez 2011; Payne 2011; Reinhardt 2010) were judged to be at unclear risk of selective 
reporting bias due to the following reasons: 
Engebretson (2011), presented incomplete data. Gaikwad (2010) did not provide the number 
of participants in each trial arm at 4 months. Four trials (Gilowski 2012; Grossi 1997; Jones 
2007; Lopez 2011) gave a graphical representation which could not be interpreted accurately. 
Han (2012) reported the primary outcome while the secondary outcome reporton baseline to 
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4 months was missing. Payne, Golub (2001) gave an incomplete report. Reinhardt (2010) 
reported on the primary outcomes, but the secondary outcomes did not have baseline values. 
OTHER POTENTIAL SOURCES OF BIAS 
Jones (2007) had 5% difference at baseline between the “Usual” treatment group and “Early” 
treatment group for the Insulin only medications. Reinhardt (2010) did not report whether the 
telephone call was recorded by the call-centre for verification purposes. 
 
EFFECTS OF INTERVENTIONS 
A total of 14 trials were included in the review including three reports of the same study 
(Golub-Lee 2008; Payne,Golub 2011; Reinhardt 2010). The trials assessed the comparison 
of antibiotics versus placebo or no antibiotic with mechanical debridement in either of the 
arms. 
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TABLE 1: SUMMARY OF FINDINGS TABLES 
Antibiotics versus no antibiotic/placebo for treatment of Chronic Periodontitis 
Antibiotics versus no antibiotic/placebo for treatment of Chronic Periodontitis 
Patient or population: Patients diagnosed with chronic periodontitis  
Setting: Tertiary Hospital 
Intervention: Systemic antibiotic  
Comparison: Placebo 
PERIOD Anticipated absolute effects*(95% CI) Relative 
effect 
(95% CI)  
№ of 
participants  
(studies)  
Certainty of 
the evidence 
(GRADE)  
Comments 
Risk with Antibiotics versus no 
antibiotic/placebo 
PD (mm) at 3 months 
assessed with: Antibiotics 
versus no antibiotics/ usual 
care in the treatment of 
periodontal disease  
follow up: 6 months 
See 
comment 
The mean PD (mm) at 3 
months in the 
intervention group was 
0.25 fewer (0.38 fewer to 
0.12 fewer) 
- 276 
(6 RCTs)  
⨁⨁◯◯ 
LOWa 
This information was not 
available 
HbA1c 
assessed with: Antibiotics 
versus no antibiotics/ usual 
care in the treatment of 
periodontal disease in 
diabetes mellitus 
follow up: median 3 months 
Moderate  - 600 
(8 RCTs)  
⨁⨁◯◯ 
LOWa,b 
This information was not 
available 
See 
comment 
See comment 
MMP_8 Study population  See 234 ⨁⨁◯◯ Information notavailable 
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Antibiotics versus no antibiotic/placebo for treatment of Chronic Periodontitis 
Patient or population: Patients diagnosed with chronic periodontitis  
Setting: Tertiary Hospital 
Intervention: Systemic antibiotic  
Comparison: Placebo 
PERIOD Anticipated absolute effects*(95% CI) Relative 
effect 
(95% CI)  
№ of 
participants  
(studies)  
Certainty of 
the evidence 
(GRADE)  
Comments 
Risk with Antibiotics versus no 
antibiotic/placebo 
assessed with: Antibiotics 
versus no antibiotics/usual 
care in the treatment of 
periodontal disease in 
diabetes mellitus 
follow up: mean 6 months 
 See 
comment 
 See comment 
comment 
(4 RCTs)  
 
LOWa This information was not 
available 
Moderate  
See 
comment 
 
See comment 
CRP 
assessed with: Antibiotics 
versus No antibiotics 
follow up: mean 3 months 
Study population  not estimable 354 
 (4 RCTs)  
⨁⨁◯◯ 
LOWa 
This information was not 
available 
See 
comment 
See comment 
Moderate  
See 
comment 
See comment 
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Antibiotics versus no antibiotic/placebo for treatment of Chronic Periodontitis 
Patient or population: Patients diagnosed with chronic periodontitis  
Setting: Tertiary Hospital 
Intervention: Systemic antibiotic  
Comparison: Placebo 
PERIOD Anticipated absolute effects*(95% CI) Relative 
effect 
(95% CI)  
№ of 
participants  
(studies)  
Certainty of 
the evidence 
(GRADE)  
Comments 
Risk with Antibiotics versus no 
antibiotic/placebo 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of 
the intervention (and its 95% CI).  
 
CI: Confidence interval; MD: Mean difference; RR: Risk ratio; MMP-8: Matrix metalloproteinase-8; CRP: C-reactive protein 
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a. Downgraded by 1 because of unclear of risk of bias, and wide confidence intervals.  
b. Downgraded by 1 because of unclear of attrition bias and reporting bias, and inadequate information on study methods. 
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PRIMARY OUTCOMES 
1. IL-1β 
Three trials reported on IL-1β (Almaghlouth2013; Golub-Lee,2008; O'Connell 2008). 
Almaghlouth (2013) assessed 40 participants (19 receiving antibiotic and remaining 21 
placebo) and observed peak values of IL-1β in four patients at baseline (values ranging from 
4.8 to 226.5 pg/ml), but no peak values were detected in any of the patients after 3 months. 
The patients in the test group received antibiotics for 7 days (three times per day). The peak 
serum amoxicillin concentration is normally reached in 1-1.5 hours post oral-administration 
with a terminal elimination half-life of 1.2 hours and 94% bioavailability (Mostafavi 2006). The 
peak serum metronidazole concentration is normally reached in 1-2 hours post oral-
administration with a half-life of 6-8 hours and 100% bioavailability (Anderson 2012). Even 
though the effect of the antibiotics were present for a short duration of 7-8 days, but during 
the time there was a peak in concentration, there was an impact on the disease. The authors 
gave no indication on how many of the four received antibiotics. Golub-Lee (2008) assessed 
GCF IL-1β levels in 128 postmenopausal women (64 in SDD antibiotic group and 64 in 
placebo group) with chronic periodontitis,however there was no significant difference in the 
median GCF IL-1β levels between the two treatment groups after 1-year or 2-years timepoint. 
O'Connell 2008 evaluated 30 participants with type 2 diabetes patients and periodontitis (15 
intervention and 15 placebo) but found no reduction in the concentration of IL-1β between 
baseline and 3 months (it remained at mean (SE) of 0.3(0.3) pg/ml); however, the trial 
authors did not give separate results for the intervention and placebo groups. 
2. IL-6 
Three trials reported IL-6 (Almaghlouth 2013; O'Connell 2008 and Payne-Golub 2011). 
Almaghlouth 2013 reported that a participant had a peak value of IL-6 of 216.3 pg/ml at 
baseline out of 40 periodontally diseased participants but there were no participants with 
peaked values after 3 months. Meanwhile, it is not clear whether the participants received 
antibiotic or placebo. O'Connell (2008) reported a decrease in IL-6 in the mean value 
(2.1;0.3(standard error (SE))  at baseline to 1.1 (0.2) at 3 months (p=0.005) for 30 participants 
with type 2 diabetes and periodontitis; however, the authors  did not give separate values for 
the  intervention group and control groups except to say “there were no significant differences 
observed between treatment groups”. Payne-Golub (2011) showed no significant difference in 
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IL-6 level between the antibiotic group (SDD) and placebo group in 128 post-menopausal 
women with chronic periodontitis after 2 years (40% SDD versus 46% placebo; OR 0.72, 
95%CI: 0.30 to 1.69, p=0.4). 
 
 
3. IL-8 
Almaghlouth (2013) reported a peak value in IL-8 (38.3 pg/ml) at baseline for one participant, 
which rose to 39.6 after 3 months; but it is not clear whether the patient received antibiotic or 
placebo. O'Connell (2008) reported a slight increase in IL-8 from mean (SE) of 9.0 (1.1) at 
baseline to 10.6 (2.5) at 3 months (p=0.621, not statistically significant) for 30 participants 
with type 2 diabetes and periodontitis; however, the trial did not give separate values for 
intervention and placebo groups except to say there were no significant differences observed 
between treatment groups. 
4. CRP 
Four trials reported on CRP (Almaghlouth 2013, Lopez 2011, Payne-Golub 2011 and Tüter 
2007). Almaghlouth (2013) observed peak values of CRP in four participants at baseline 
(values ranging from 13.4 to 52.6 µg/ml) and in three participants at 3 months (14.1 to 33.4 
µg/ml); the trial authors gave no indication of how many of the participants with these peak 
values received antibiotics. Lopez (2011) assessed C-reactive protein (CRP) levels in 
participants with metabolic syndrome 82 participants received amoxicillin and metronidazole 
while the control group (83 participants) received placebo. Although the mean CRP levels 
decreased significantly at 9 and 12 months, at 3months, there were no significant differences 
between the two treatment groups. Payne-Golub (2011), the SDD antibiotic intervention 
significantly reduced median hs-CRP by 18% over a period of two years compared to the 
placebo the ratio of medians of SDD versus placebo (0.82, 95%CI: 0.70 to 0.97, p=0.02). 
Tüter, (2007) also assessed the effect of the SDD antibiotic on hs-CRP compared to placebo; 
however, although there were significant improvements between baseline and 6 weeks in 
both groups, but there was no significant difference between groups at 6 weeks (p=0.628). 
5. MMP-8 
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Four trials reported MMP-8 (Gilowski2012; Golub-Lee 2008; Han 2012; Tüter 2007). Gilowski 
(2012) randomized 34 participants (17 receiving SDD and 17 receiving placebo) with chronic 
periodontitis and type 2 diabetes; although MMP-8 decreased significantly between baseline 
and three months among the SDD group while an increase was observed in the placebo 
group, there was no significant difference between the two groups. Golub-Lee (2008), the 
SDD significantly reduced the odds of increased MMP-8 levels by 60% compared to placebo 
during the 2-year period of study (OR 0.40, 95%CI: 0.21 to 0.77, p=0.006) among the 128 
menopausal women with periodontitis (64 in each group). Han (2012), 36 participants with 
generalized chronic periodontitis (18 receiving azithromycin and 18 receiving placebo) 
showed no significant differences in GCF MMP-8 concentration between the two treatment 
groups from baseline to 6 months. Tüter (2007) demonstrated no significant differences in 
MMP-8 between the SDD and placebo group among the 36 participants with chronic 
periodontitis at pre- and post 6-week time points. 
6. TIMP-1 
One trial (Payne,Golub 2011) reported TIMP-1; there was no significant difference between 
the antibiotic group (SDD) and placebo group TIMP-1 among the 128 postmenopausal 
women with chronic periodontitis after 2 years; ratio of medians of SDD versus placebo (0.96, 
95%CI: 0.78 to 1.18, p=0.7). 
7. HbA1c 
Eight trials reported HbA1c levels. In the study from Gaikwad (2010), there was no significant 
difference in HbA1c levels (%) at 4 months of treatment between the SDD and placebo 
groups among the 50 participants with type 2 diabetes and chronic generalized periodontitis 
(Mean (SD) 7.00 (0.76) SDD versus 7.11 (0.99) Placebo; p=0.710); however, the different 
sample sizes in each treatment group were not given at 4 months. Gilowski (2012) also found 
no significant difference in HbA1c (%) at 3 months after treatment with SDD compared to 
placebo among 34 patients with type 2 diabetes and chronic periodontitis (Median 
(Interquartile Range [IQR]) 6.3 (5.5,7.3) SDD versus 6.7 (6.3, 7.7) Placebo; p=0.8). Jones 
(2007) evaluated the effect of SDD versus placebo after 4 months of treatment among 165 
veterans (83 receiving SDD antibiotic and 82 placebo) with periodontitis and poorly controlled 
diabetes, they found no significant difference in the percent achieving either HbA1c 
decreases of either > 0.5 or > 1.0 (55% versus 52% (p=0.38) or 41% versus 34% (p=0.31), 
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respectively). In Botero (2013), the antibiotic group had a reduction of 0.8% versus 0.3% in 
the placebo group; however, no comparison p-value was calculated between the two 
treatment groups. Also Engebretson (2011), the SDD antibiotic group (n=15) had a reduction 
in HbA1c levels (%) from baseline to 3 months of 0.9% versus 0% in the placebo group; 
however, there was no significant difference between the treatment groups (p=0.22). Grossi 
(1997), had 113 Native Americans with periodontal disease and type 2 diabetes participants 
that were randomized into three SDD groups and two placebo groups; all the three SDD 
groups showed significant reduction in HbA1c (%) of approximately 10% at 3 months while 
the placebo groups did not show significant reductions; however, no comparisons were made 
between the SDD and placebo groups. Miranda (2014) assessed the effect of metronidazole 
+ amoxycillin versus placebo among 58 (29 per group) type 2 diabetic participants with 
periodontitis but found no significant difference in HbA1c levels (%) between the two 
treatment groups at baseline, 3 months, 6 months, and after 1 year of treatment (p=0.35, 
0.55, 0.33, and 0.62, respectively).O'Connell 2008 found no significant difference in HbA1c 
(%) improvement between the SDD group (1.5%) and placebo group (0.9%) after 3 months 
among 30 type 2 diabetes participants with periodontitis. 
 
SECONDARY OUTCOMES 
1. Probing Depth (PD)  
(a) PD (mm) 
Ten trials reported probing depth (PD, in mm). A total of six trials (Almaghlouth 2013, Botero 
2013, Gaikwad 2010, Miranda 2014, O'Connell 2008, Saleh 2016) measured PD (mm) at 3 
months and a random effects meta-analysis of these trials yielded a significant antibiotic 
effect of reducing PD by 0.24 mm (Mean Difference [MD] -0.25mm, 95% confidence interval 
[CI]: -0.38mm to -0.12mm, n=276 participants, 6 trials,(Analysis 1.1)and there was no 
significant heterogeneity between trials (Chi2=5.75, degrees of freedom [df]=5, p=0.33, 
I2=13%). Gilowski (2012) also assessed PD (mm) at 3 months but there were no significant 
differences between treatment groups; the results are only reported in a figure (box and 
whisker plot) from which values for analysis cannot be accurately extracted. One trial (Han 
2012) measured PD reduction (in mm) from baseline to 3 months and found no significant 
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difference between antibiotic and placebo groups (MD 0.25mm, 95% CI -0.05mm to 0.55mm 
(Analysis 1.2). One trial (Grossi 1997) reported a PD reductions at 3 months of 17%, 23%, 
and 22% for three antibiotic treatment groups (H2O-doxycycline, CHX-doxycycline, and 
Iodine-doxycycline, respectively), compared to 15% for the placebo control group. Tüter 
(2007) found statistically significant improvements in PD (mm) after 6 weeks of treatment in 
favor of the antibiotic group compared to placebo (Median (IQR) of 3.45 (3.24 to 3.69) mm 
SDD versus 3.78 (3.52 to 4.2) mm Placebo, p=0.034, n=36 participants (18 per group). 
Miranda (2014) also assessed the antibiotic effect at 6 months and 1 year but found no 
significant difference between groups (data not reported). 
 
(b) PD≤3mm  
Two trials (Botero 2013; O'Connell 2008) measured the number of sites with PD ≤ 3mm at 3 
months but found no significant difference in the mean number of sites between the antibiotic 
and placebo groups (MD -1, 95% CI: -22.54 to 20.53, n=98 participants, 2 trials,(Analysis 
1.3) and there was no significant heterogeneity between trials (Chi2=1.71, df=1, p=0.19, 
I2=41%). 
(c) PD≥4mm  
Almaghlouth (2013) and Botero (2013) measured the number of sites with PD≥4mm after 3 
months and found significantly greater reduction in the mean number of sites in favour of the 
antibiotic group (MD -3.38, 95% CI: -6.51 to -0.25, n=108 participants, 2 trials,(Analysis 1.4) 
and there was no significant heterogeneity between studies (Chi2=0.01, df=1, p=0.93, I2=0%). 
In Gilowski (2012), the SDD group had a significantly greater reduction in the mean number 
of sites with PD≥4mm (p=0.02); however the values were given in a figure from which 
accurate values for Mean (SD) could not be extracted. For Lopez (2011), there was a 
significant improvement in favor of antibiotic treatment at 3, 6, 9, and 12 months (data not 
reported). 
2. CAL 
Eight trials reported clinical attachment level (CAL). Four trials (Gaikwad 2010, Miranda 2014, 
O'Connell 2008, Saleh 2016) measured CAL (mm) at 3 months and a random effects meta-
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analysis of these trials showed no significant difference in CAL (MD -0.13, 95% CI: -0.34 to 
0.07, n=168 participants, 4 trials,(Analysis 1.5); there was no significant heterogeneity 
between the trials (Chi2=0.98, df=3, p=0.81, I2=0%). Gaikwad (2010) also measured CAL 
(mm) at 4 months and found a significant reduction in favor of the antibiotic group (MD -0.30, 
95%CI: -0.55 to -0.05, 50 participants(Analysis 1.5). However, Miranda (2014) did not find 
significant difference between treatment groups at both month 6 (MD -0.30, 95%CI: -0.77 to 
0.17, 56 participants,(Analysis 1.5) and month 12 (MD -0.40, 95%CI: -0.87 to 0.07, 56 
participants,(Analysis 1.5). 
Han, (2012) measured the reduction in mean CAL (mm) but there were no significant 
differences between the treatment groups at month 1 (MD 0.11, 95%CI: -0.20 to 0.42, 28 
patients,(Analysis 1.6),month 3 (MD 0.10, 95%CI: -0.28 to 0.48, 28 participants,(Analysis 
1.6), and month 6 (MD 0.01, 95%CI: -0.36 to 0.38, 28 patients,(Analysis 1.6). Gilowski 
(2012), demonstrated there was no significant difference in CAL between groups (values only 
given in a figure). The Grossi (1997) trial, had three treatment groups that demonstrated  CAL 
improvement of 12,18, and 14% at month 6 whereas the placebo group showed 6 and 9% 
improvement at 3 and 6 months; there were no values given to compare between intervention 
and control groups. Tüter (2007) found no significant difference in CAL (mm) between the 
antibiotic and placebo groups after 6 weeks of treatment (Median (IQR) of 3.97 (3.75 to 4.10) 
mm SDD versus 4.0 (3.66 to 4.46) mm Placebo, p=0.521, n=36 participants (18 per group). 
3. Gingival Index (GI) 
Gaikwad (2010), reported no significant difference in gingival index (GI) between the 
antibiotic and placebo group at month 1 (p=0.858), month 2 (p=0.252), month 3 (p=0.063), 
and month 4 (p=0.219); however, we could not calculate the treatment effect since the 
respective number of participants in each group after baseline were not given. Grossi(1997) 
reported that at 6 months, the antibiotic groups had a significantly greater number of 
participants with no detectable P. gingivalis compared to the control groups (data not 
available). Tüter (2007) reported significantly reduce GI in the antibiotic group after 6 weeks 
of treatment compared to the placebo group (Median (IQR) of 1.00 (0.77 to 1.16) SDD versus 
1.27 (0.97 to 1.52) Placebo, p=0.027, n=36 participants (18 per group)). 
4. Plaque Index (PI) 
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Gaikwad (2010), demonstrated no significant difference in plaque index (PI) between the 
antibiotic and placebo group at month 1 (p=0.459), month 2 (p=0.729), month 3 (p=0.076), 
and month 4 (p=0.052); however, we could not calculate the treatment effect since the 
respective number of participants in each group after baseline were not given. Botero (2013) 
measured plaque score and there was no significant difference between the antibiotic and 
control groups at month 3, month 6, and month 9 (Analysis 1.7). Grossi (1997) found 
significant reductions in plaque accumulation in all study groups but did not compare the 
antibiotic versus the placebo groups. Lopez (2011) measured the mean percent sites with 
plaque at 3, 6, 9, and 12 months and only found significant improvement at 12 months in 
favor of the antibiotic group compared to the placebo group (data was in graphic only). 
O'Connell (2008) found no significant difference in PI percent reduction at 3 months between 
the antibiotic and placebo groups (MD 8.60, 95%CI: -3.40 to 20.60, 30 participants,(Analysis 
1.8). Saleh (2016) found no significant difference in full mouth plaque score (FMPS [%]) at 3 
months between the antibiotic and placebo groups (MD -7.95, 95%CI: -21.75 to 5.85, 32 
participants, (Analysis 1.9). Tüter (2007) found no significant difference in PI between the 
antibiotic and placebo groups after 6 weeks of treatment with SDD (Median (IQR) of 0.55 
(0.17 to 1.0) versus 0.75 (0.23 to 0.92) in the control group;, p=0.696, n=36 participants (18 
per group). 
 
TABLE 2: ANTIBIOTICS VERSUS NO ANTIBIOTIC/PLACEBO -ANALYSIS  
Outcome or Subgroup Studies 
Participan
ts 
Statistical Method 
Effect 
Estimate 
1.1 PD (mm) at 3 months 6 276 Mean Difference (IV, 
Random, 95% CI) 
-0.25 [-0.38, -
0.12] 
1.2 PD Reduction (in 
mm) from baseline to 3 
1 28 Mean Difference (IV, 
Random, 95% CI) 
0.25 [-0.05, 
0.55] 
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months 
1.3 Number of sites with 
PD ≤ 3mm at 3 months 
2 98 Mean Difference (IV, 
Random, 95% CI) 
-1.00 [-22.54,
20.53] 
1.4 Number of sites with 
PD≥4mm at 3 months 
2 108 Mean Difference (IV, 
Random, 95% CI) 
-3.38 [-6.51, -
0.25] 
1.5 CAL (mm) 4 330 Mean Difference (IV, 
Random, 95% CI) 
-0.23 [-0.37, -
0.08] 
 1.5.1 Month 3 4 168 Mean Difference (IV, 
Random, 95% CI) 
-0.13 [-0.34,
0.07] 
 1.5.2 Month 4 1 50 Mean Difference (IV, 
Random, 95% CI) 
-0.30 [-0.55, -
0.05] 
 1.5.3 Month 6 1 56 Mean Difference (IV, 
Random, 95% CI) 
-0.30 [-0.77,
0.17] 
 1.5.4 Month 12 1 56 Mean Difference (IV, 
Random, 95% CI) 
-0.40 [-0.87,
0.07] 
1.6 Reduction in mean 
CAL (mm) 
1 84 Mean Difference (IV, 
Random, 95% CI) 
0.08 [-0.12, 
0.28] 
 1.6.1 Month 1 1 28 Mean Difference (IV, 0.11 [-0.20, 
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Random, 95% CI) 0.42] 
  1.6.2 Month 3 1 28 Mean Difference (IV, 
Random, 95% CI) 
0.10 [-0.28, 
0.48] 
  1.6.3 Month 6 1 28 Mean Difference (IV, 
Random, 95% CI) 
0.01 [-0.36, 
0.38] 
1.7 Plaque score 1 191 Mean Difference (IV, 
Random, 95% CI) 
2.71 [-2.60, 
8.02] 
  1.7.1 3 Months 1 68 Mean Difference (IV, 
Random, 95% CI) 
2.47 [-5.97, 
10.91] 
  1.7.2 6 Months 1 64 Mean Difference (IV, 
Random, 95% CI) 
0.10 [-9.58, 
9.78] 
  1.7.3 9 Months 1 59 Mean Difference (IV, 
Random, 95% CI) 
5.60 [-4.03, 
15.23] 
1.8 PI percent reduction 
at 3 months 
1 30 Mean Difference (IV, 
Random, 95% CI) 
8.60 [-3.40, 
20.60] 
1.9 FMPS (%) 1 32 Mean Difference (IV, 
Random, 95% CI) 
-7.95 [-21.75, 
5.85] 
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TABLE 3: FOREST PLOTS FOR MECHANICAL DEBRIDEMENT COMBINED 
WITH ANTIBIOTICS IN THE TREATMENT OF PERIODONTITIS: EFFECT ON 
SYSTEMIC BIOMARKERS 
 
PD at 3 months (mm) 
 
 
PD Reduction from Baseline to 3 months (mm) 
 
Number of sites with PD ≤ 3mm at 3 months 
Study or Subgroup
Almaghlouth 2013
Botero 2013
Gaikwad 2010
Miranda 2014
O'Connell 2008
Saleh 2016
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 5.75, df = 5 (P = 0.33); I² = 13%
Test for overall effect: Z = 3.82 (P = 0.0001)
Mean
2.6
2.3
3.16
2.6
1.9
3.04
SD
1
0.6
1.54
0.2
0.3
0.2
Total
19
32
25
29
15
22
142
Mean
2.9
2.5
2.85
3
2.1
3.33
SD
1.3
0.5
0.2
0.5
0.3
0.55
Total
21
36
25
27
15
10
134
Weight
3.2%
20.3%
4.4%
31.2%
28.4%
12.4%
100.0%
IV, Random, 95% CI
-0.30 [-1.02, 0.42]
-0.20 [-0.46, 0.06]
0.31 [-0.30, 0.92]
-0.40 [-0.60, -0.20]
-0.20 [-0.41, 0.01]
-0.29 [-0.64, 0.06]
-0.25 [-0.38, -0.12]
Antibiotic Placebo Mean Difference Mean Difference
IV, Random, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours antibiotic Favours placebo
Study or Subgroup
Han 2012
Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.65 (P = 0.10)
Mean
1.79
SD
0.4
Total
14
14
Mean
1.54
SD
0.4
Total
14
14
Weight
100.0%
100.0%
IV, Random, 95% CI
0.25 [-0.05, 0.55]
0.25 [-0.05, 0.55]
Antibiotic Placebo Mean Difference Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours placebo Favours antibiotic
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Number of sites with PD ≥ 4mm at 3months 
 
 
CAL (mm) measurements at months 3, 6, 8 & 12 
Study or Subgroup
Botero 2013
O'Connell 2008
Total (95% CI)
Heterogeneity: Tau² = 109.66; Chi² = 1.71, df = 1 (P = 0.19); I² = 41%
Test for overall effect: Z = 0.09 (P = 0.93)
Mean
119
105.8
SD
36.8
48
Total
32
15
47
Mean
111.9
121.7
SD
35.2
34.5
Total
36
15
51
Weight
64.8%
35.2%
100.0%
IV, Random, 95% CI
7.10 [-10.07, 24.27]
-15.90 [-45.81, 14.01]
-1.00 [-22.54, 20.53]
Antibiotic Placebo Mean Difference Mean Difference
IV, Random, 95% CI
-50 -25 0 25 50
Favours placebo Favours antibiotic
Study or Subgroup
Almaghlouth 2013
Botero 2013
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.93); I² = 0%
Test for overall effect: Z = 2.11 (P = 0.03)
Mean
3.3
4.3
SD
5.1
7.8
Total
19
32
51
Mean
6.8
7.5
SD
7.8
12.7
Total
21
36
57
Weight
59.9%
40.1%
100.0%
IV, Random, 95% CI
-3.50 [-7.55, 0.55]
-3.20 [-8.15, 1.75]
-3.38 [-6.51, -0.25]
Antibiotic Placebo Mean Difference Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Favours antibiotic Favours placebo
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DISCUSSION 
SUMMARY OF MAIN RESULTS 
The primary objective of this study was to assess the effectiveness of systemic antibiotics as 
an adjunctive therapy to mechanical debridement in the changes of inflammatory systemic 
biomarkers as compared to mechanical debridement alone in chronic periodontitis. We 
included 14 trials consisting of 1457 participants in the analysis for this review. 
The trials compared antibiotics versus placebo or no antibiotic, with mechanical debridement 
in either arm of the intervention. The participants in the trials included healthy individuals, 
menopausal women and patients with co-morbidities such as type2 diabetes and CVD. Three 
Study or Subgroup
1.5.1 Month 3
Gaikwad 2010
Miranda 2014
O'Connell 2008
Saleh 2016
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.98, df = 3 (P = 0.81); I² = 0%
Test for overall effect: Z = 1.25 (P = 0.21)
1.5.2 Month 4
Gaikwad 2010
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.32 (P = 0.02)
1.5.3 Month 6
Miranda 2014
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
1.5.4 Month 12
Miranda 2014
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.66 (P = 0.10)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.74, df = 6 (P = 0.84); I² = 0%
Test for overall effect: Z = 3.09 (P = 0.002)
Test for subgroup differences: Chi² = 1.76, df = 3 (P = 0.62), I² = 0%
Mean
2.96
3.8
9.8
3.89
2.69
3.7
3.7
SD
0.45
0.9
1.6
0.71
0.42
0.9
0.9
Total
25
29
15
22
91
25
25
29
29
29
29
174
Mean
3.03
4.1
9.7
4.08
2.99
4
4.1
SD
0.51
0.8
1.4
0.69
0.49
0.9
0.9
Total
25
27
15
10
77
25
25
27
27
27
27
156
Weight
29.1%
10.4%
1.8%
7.6%
49.0%
32.4%
32.4%
9.3%
9.3%
9.3%
9.3%
100.0%
IV, Random, 95% CI
-0.07 [-0.34, 0.20]
-0.30 [-0.75, 0.15]
0.10 [-0.98, 1.18]
-0.19 [-0.71, 0.33]
-0.13 [-0.34, 0.07]
-0.30 [-0.55, -0.05]
-0.30 [-0.55, -0.05]
-0.30 [-0.77, 0.17]
-0.30 [-0.77, 0.17]
-0.40 [-0.87, 0.07]
-0.40 [-0.87, 0.07]
-0.23 [-0.37, -0.08]
Antibiotic Placebo Mean Difference Mean Difference
IV, Random, 95% CI
-1 -0.5 0 0.5 1
Favours antibiotic Favours placebo
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studies reported no significant difference in the level of GCF IL-1β between the two treatment 
groups. At the 3-month follow-up, the probing depth (PD) of periodontal pockets≥4mm 
revealed significant decrease. The CAL, GI and PI showed negligible improvement. 
Adjunctive administration of antibiotics for a minimum of 3 months also showed substantial 
improvement on the clinical parameters of PD as compared to mechanical debridement 
alone. SDD demonstrated a significant reduction (60%) in the odds of increased MMP-8 
levels compared to placebo during the 2-year period of study. A significant reduction in MMP-
8 level was observed in type 2 diabetes at baseline and at the 3-month follow-up in the 
treatment group. However, there was no significant difference between the two groups. TIMP-
1 levels are inversely linked to MMP-8 levels. Although there were no significant differences 
between the antibiotic group and placebo groups, one trial demonstrated a significant 
increase in saliva and GCF of TIMP-1 concentration after initial periodontal treatment in 
healthy participants. 
Relapse data: Some of the studies show some regression in the course of the study. Botero 
(2013), observed a relapse in the test group (Az-Prof) and placebo group (Pb-Sca) at 6 and 9 
months regarding the HbA1c levels. However, there was no relapse in the test group Az-Sca 
at 6 and 9 months. Details of the relapse were not reported. 
OVERALL COMPLETENESS AND APPLICABILITY OF EVIDENCE 
Due to the poorly recorded methodological rigour and reporting of data, it is difficult to assess 
the applicability of those results. Overall, there is insufficient evidence to make general 
conclusions on the effects of adjunctive antibiotics on systemic biomarkers in the treatment 
periodontitis.  
QUALITY OF THE EVIDENCE 
The overall quality of evidence on primary outcomes (changes in serum/blood levels of 
inflammatory biomarkers such as MMPs, TIMPs, Cytokines, CRP and HbA1c) was low due to 
"unclear" risk of bias/ high risk of bias. Twelve of the included trials in this review lacked 
methodological rigour and results were not explicitly reported. Two trials (Miranda 2014; 
Saleh 2016) had low risk of bias, a number of the trials were not amenable to meta-analysis 
due to insufficient data while others did not indicate whether the reported values were for the 
effect of intervention in the treatment group or the placebo group. Some of the results were 
presented in box and whisker plots (Almaghlouth 2013; Golub,Lee 2008; O’Connell 2008) 
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making data extraction for analysis difficult. Only one of the four trials on CRP demonstrated 
a significant reduction (18%) over 2-years in the treatment group. MMP-8 demonstrated a 
significant difference in 1 trial, while IL-6 level was non-significant after 3 months. The HbA1c 
levels displayed non-significant differences between treatment groups. We used GRADE 
Profiler (GRADEpro 3.6) software to assess the quality of evidence on HbA1c, MMP-8, CRP 
and probing depth at 3 months (PD) by rating the quality of evidence, see Summary of 
findings table. We decided to downgrade by 1, for imprecision and risk of bias because of the 
wide confidence interval and loss to follow up in the studies (Attrition bias). Grading of the 
evidence considers factors such as study limitations, imprecision, inconsistency, indirectness 
of results and selective reporting (Guyatt2011). The quality of evidence for the selected 
outcomes was “low” suggesting that further research is likely to have an important impact on 
our confidence in the estimate of effect and is likely to change the presented estimate. 
POTENTIAL BIASES IN THE REVIEW PROCESS 
Attempts were made to minimise potential bias in this review in several ways. We conducted 
a comprehensive and exhaustive trial search to identify trials for inclusion in this review. We 
included published and unpublished trials in all languages, study search result records were 
screened in duplicate and all decisions on inclusion of each trial was confirmed by a third 
review author. As far as possible, we adhered to the agreed standardised data extraction 
format with at least two review authors assessing the quality, accuracy and consistency of the 
content according to the original articles. We cross checked references of existing literature to 
ensure that the previously identified studies were appraised for inclusion in this review. 
Authors of studies were contacted when more information was required to make explicit 
judgement, however not all authors responded. At least two review authors independently 
scrutinised and selected trials for inclusion in the review using eligibility criteria, assessed risk 
of bias, and extracted data. Risk of bias judgments and decision was explicitly done using the 
risk of bias table and graph. GRADEpro software was used to assess the quality of evidence, 
subjective judgement and decisions on risk of bias was done explicitly with the aid of risk of 
bias table. 
 
AGREEMENTS AND DISAGREEMENTS WITH OTHER STUDIES 
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This is a systematic review on the effect of adjunctive antibiotic on systemic biomarkers in the 
treatment of chronic periodontitis. The intervention produced a mean reduction in probing 
depth (PD≥4mm) of 3.38mm in the periodontal pockets in the SRP+antibiotic group after 3 
months in 2 trials (Almaghlouth 2013; Botero 2013). Those were included in a meta-analysis, 
which showed an effect estimate as MD -3.38 with 95% CI -6.51 to -0.25 (p=0.93). 
The meta-analysis favoured combined SRP with systemic antibiotic therapy in terms of 
reduction of inflammatory markers, as it indicated inflammatory changes. These findings are 
supported by Polimeni (2006) who concluded that clinical attachment gains are the result of 
the resolution of inflammation, bone filling and the formation of long junctional epithelium. 
The mean reduction in probing depth (PD ) concurs with the synergistic effect of antibiotics 
together with SRP. Xiao & Graves (2015) stated that antibiotics improve periodontal healing 
whilst having a bacteriostatic effect on the target microbial species along with mechanical 
debridement, which in turn strengthens the immune system. Furthermore, Grellmann (2016) 
and Kolakovic (2014) reported that PD is more likely to show a significant reduction with 
antibiotic therapy in periodontal treatment than CAL. However, the study by Haffajee (2003), 
a systematic review of 29 trials (36 comparisons) assessed the effect of local and systemic 
antibotics in the treatment of periodontitis. The review by Haffajee (2003) reported a gain in 
the clinical attachment level and a reduction in pocket depth (PD). Herrera et al.(2002) is 
another systematic review which examined the effect of antibiotics on both aggressive and 
chronic periodontitis, the authors reported on  CAL and PPD.. Additionally, Ashley (1999), 
Caton (2000), Caton (2001), Choi (1994), Crout (1996), Emingil (2004), Gorska (2006), 
Novak (2002) and Lee (2004) concluded that antibiotic administration improves PD and CAL 
values in periodontitis. 
 
The current review agrees with Chen (2000), Gorska (2006) and Makela (1994) that systemic 
antibiotic decreases the MMP levels in the treatment of chronic periodontal disease.  
Also, the significant increase in GCF of TIMP-1 agreed with Hayakawa et al.(1994) who 
confirmed a significant increase in saliva and GCF of TIMP-1 concentration after initial 
periodontal treatment with systemic antibiotics. 
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The CRP biomarkers in the included trials were not amenable to meta-analysis. In support of 
the findings from this review, which was the reduction in CRP levels after therapy in Lopez 
(2011), Payne (2011) and (Tüter 2007), Mattila (2002) measured the CRP and fibrinogen 
levels in 35 patients with adult periodontitis where the authors reported that adjunctive 
antibiotics decreased CRP levels. Mattilla (2002) concluded that only “susceptible” individuals 
react to periodontitis with an increase in CRP and the susceptible individuals may not 
necessarily have a severe form of the disease. In such individuals, treating periodontitis 
lowers the CRP levels and possibly reduced their CHD risk. Matilla (2002) postulated that an 
elevated CRP in periodontal disease may be individual-specific or genetically specific. The IL-
6 biomarker analysis included 3 trials which were not amenable to meta-analysis. All 3 trials 
revealed non-significant differences between treatment groups after 3 months. Brown (2004), 
demonstrated decreased IL-6 levels at 6 months in the SDD treated patient, however, the 
placebo treated patients did not show significant differences. Overall, there was a 32% 
reduction in IL-6 levels. It must be noted that Brown (2004) was a pilot RCT and was not 
powered to detect a difference in clinical endpoints. 
IL-6 and CRP are closely associated (Brown 2004). IL-6 induces the production and release 
of CRP. The SDD therapy thus reduced IL-6 and CRP and this may have been due to IL-6 
being inhibited upstream. In this study, the CRP was reduced by 46% in the SDD group 
whereas there was no significant reduction in the placebo group. 
Choi (2004) reported no significant differences in the 1L-6 levels due to SRP+SDD use. Non-
significant differences were observed in the IL-1β biomarker between the treatment groups at 
3 months. However, Cazalis (2008) reported a significant decrease (P<0.05) in the secretion 
of IL-1β, IL-6, IL-8 & TNF-α and Goutoudi (2004), reported a decreased IL-1β level after SRP 
alone (P<0.01).  
The HbA1c biomarker demonstrated a significant difference in the experimental group which 
was supported by Stewart (2001). The results yielded were a 17.1 and 6.7% reduction in the 
HbA1c levels in the treatment and control groups respectively. However, Promsudthi (2005) 
reported a non-significant reduction in HbA1c levels after 3 months. 
.  
IMPLICATIONS FOR PRACTICE 
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The limited available evidence shows that adjunctive administration of antibiotics for a 
minimum of 3 months improve PD clinical parameters substantially compared to mechanical 
debridement alone. Similarly, the extendedtwo-year duration of adjunctive SDD with 
mechanical debridement shows an improvement in the systemic CRP and MMPs serum 
levels. 
 
IMPLICATIONS FOR RESEARCH 
The included trials reported on the following outcomes: serum/blood levels of MMPs, TIMPs, 
Cytokines, CRP, IL-1β, IL-6, IL-8, CRP, HbA1c, PD and GI. Further rigorous and well 
conducted large randomised controlled trials of high quality would be beneficial to assess the 
effect of adjunctive antibiotics administration on systemic biomarkers in chronic periodontitis. 
Majority of the included trials are of poor methodological quality and the results were 
portrayed in figures/illustrations, making it difficult to extract the data accurately. This limits 
the applicability of the result in clinical evidence-based practice. 
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CHARACTERISTICS OF STUDIES 
Characteristics of included studies 
ALMAGHLOUTH 2013 
Methods  Study design: Randomised controlled trial 
Trial duration: 3 months 
Trial location: School of Dental Medicine of the University of Geneva, 
Switzerland 
Participants  Number of participants: 40 healthy participants with moderate-to-
advanced periodontitis or patient seeking routine dental check-up, aged 
25 -70 years. Presence of at least 4 teeth with a probing pocket depth 
(PD) of >4mm, clinical attachment loss of at least 2mm, and 
radiographic evidence of bone loss. (April 2009 and August 2011) 
Intervention group: 19 participants 
Control group: 21 participants. 
Interventions  Intervention: 500mg Metronidazole+ 375mg Amoxicillin three times a 
day for 7 days. 
Supragingival plaque & calculus removed and oral hygiene instructions 
given. 
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Periodontally diseased teeth were SRP-treated to the depth of the 
pocket under local anaesthesia 
Ultrasonic instruments & Gracey curettes used and pockets irrigated 
with 0.1% aqueous solution of chlorhexidine. 
Mouth rinse for next 10 days with 0.2% Chlorhexidine. 
SRP completed within 48 hours & 2 sessions were required for each 
participant. 
Control: Supragingival plaque & calculus removed and oral hygiene 
instructions given. 
Periodontally diseased teeth were SRP-treated to the depth of the 
pocket under local anaesthesia. 
Ultrasonic instruments & Gracey curettes used and pockets irrigated 
with 0.1% aqueous solution of chlorhexidine. 
Mouth rinse for next 10 days with 0.2% Chlorhexidine. SRP completed 
within 48 hours & 2 Sessions were required for each participant. 
Outcomes  Primary outcomes: Changes in circulating IL-1β, IL-6, IL-8 and CRP 
after therapy, with or without antibiotics 
Secondary outcomes: Probing pocket depth/probing depth (PPD/PD)  
Notes  The study was supported by Swiss National Foundation 
 
Risk of bias table  
Bias 
Authors' 
judgement Support for judgement 
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Random sequence 
generation (selection 
bias) 
Low risk 
Quote: "Computer generated code allocation was 
used" 
Allocation concealment 
(selection bias) 
Low risk Quote: "Computer-generated randomization list was 
concealed to the patient, the clinical examiner and the 
Therapist" 
Blinding of participants 
and personnel 
(performance bias) 
Low risk 
Participants were masked, the dentist,dental 
technician and dental assistant were masked 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk 
It was not reported whether the assessor was masked 
or not 
Incomplete outcome 
data (attrition bias) 
Low risk All randomised participants were included in the final 
analysis 
Selective reporting 
(reporting bias) 
High risk In the case of IL-6, it is not clear whether the patient 
was receiving antibiotic or placebo -OR- there was no 
indication of how many of the patients having peak 
values received antibiotics. 
Other bias Low risk Non-significant 
 
BOTERO 2013 
Methods Study design: Randomised clinical trial 
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Trial duration: January 2011 to July 2012 
Trial location: San Vicente de Paul Hospital Medeliin, Coloumbia. 
Participants Number of participants: 105 participants, 3-arms. 
Adults diagnosed with moderate periodontitis + type 1 and type 2 
diabetes for duration of 2 years and above. Minimum of 10 teeth 
present. 
Moderate periodontitis was defined as 2 or more inter-proximal sites 
with clinical attachment level of 4mm or more not on the same tooth, 
or 2 or more inter-proximal sites with probing depth of 5mm or more, 
not on the same tooth. 
Non-surgical therapy(NSPT)+ Azithromycin(AZ)- [AZ-Sca] = 33 
Azithromycin + Prophylaxis - [AZ-Pro] = 35 
Non-surgical therapy(NSPT)+Placebo - [AZ-PbSca] = 37 
Interventions Interventions: 
Group #1: (AZ-Sca Group): Subgingival scaling with an ultrasonic 
device till smooth root surface. 
Polishing after supragingival scaling. 
Azithromycin tablet 500mg daily for 3 days consecutive days from the 
day of the intervention. 
Group #2: (AZ-Pro): Supragingival prophylaxis 
Azithromycin tablet 500mg daily for 3 days since intervention date. 
Subgingival scaling at the end of the study. 
Control Group: (PB-Sca Group): Subgingival scaling with an 
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ultrasonic device till smooth root surface. 
Polishing after supragingival scaling. 
Placebo-tablet 1 daily for 3 days since intervention date. 
Outcomes Primary outcomes: Changes in the circulating glycosylated 
haemoglobin level (HbA1c). 
Secondary outcomes: Probing depth (PD) and plaque scores. 
Notes The name of the placebo was not provided 
 
Risk of bias table  
Bias 
Authors' 
judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk 
Computer-generated table with permutations in block of 
4 was used. It was stratified by gender. 
Allocation 
concealment 
(selection bias) 
Low risk 
Opaque, sealed and coded envelope used to conceal 
the assignment. 
Blinding of 
participants and 
personnel 
(performance bias) 
Low risk 
Participants: Blinded, Dentist / dental technician/dental 
assistant blinded to the type of pharmacological 
treatment. 
Blinding of outcome Low risk Method used to conceal the assignment from outcome 
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assessment 
(detection bias) 
Assessor was not described (but the assessor was 
blinded as per study). 
Incomplete outcome 
data (attrition bias) 
Unclear risk Loss to follow-up was described adequately. The loss to 
follow-up from each group was described as follows - 
AZ-Sca group = 5 participants (15%); AZ-Pro group = 
4participants (11%) and PB-Sca group = 6 (16%) 
Selective reporting 
(reporting bias) 
High risk In the case of HbA1c, no comparison p-value was 
calculated between the two treatment groups. 
Other bias Unclear risk The authors did not provide information whether the 
opaque envelope was sequentially numbered to ensure 
adequate concealment. 
 
ENGEBRETSON 2011 
Methods Study design: Randomised controlled trial 
Trial duration: 3 months 
Trial location: Naomi Berrie Centre and Department of Periodontics, 
Columbia University Medical Centre, USA. 
Participants Number of participants: 45 Type 2 diabetic individuals with untreated 
chronic periodontitis seeking routine maintenance visits with 
physician, aged 50-56 years. Type 2 diabetes diagnosed 6 months 
previously. Intake of prescribed oral medications or insulin for at least 
3 months. Loss of clinical attachment >5mm in at least one site in 
each jaw quadrant. 
Intervention group 1: 15 participants 
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Intervention group 2: 15 participants 
Control group: 15 participants. 
Interventions Interventions: 
Group #1: 20mg SDD b.i.d x 3 months. 
Full-mouth scaling and root planing with curettes and ultrasonic 
instruments under local anaesthesia for 2 hours. 
Blood and clinical parameters collected at 1 month and 3 months 
respectively. 
Group #2: 100mg ADD daily x 3 months. 
Full-mouth scaling and root planing with curettes and ultrasonic 
instruments under local anaesthesia for 2 hours. 
Blood and clinical parameters collected at 1 month and 3 months 
respectively. 
Control Group: Placebo daily x 3 months. 
Full-mouth scaling and root planing with curettes and ultrasonic 
instruments under local anaesthesia for 2 hours. 
Blood and clinical parameters collected at 1 month and 3 months 
respectively. 
Outcomes Primary outcomes: Changes in the circulating glycosylated 
haemoglobin level (HbA1c) 
Secondary outcomes: PD, Clinical attachment loss (CAL) and 
percentage sites with plaque were measured at baseline only and no 
data was provided for 3 or 6 months post-baseline. 
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Notes The name of the placebo was not provided. 
 
 
 
Risk of bias table  
Bias 
Authors' 
judgement Support for judgement 
Random sequence 
generation (selection bias) 
Low risk Random assignment by way of computer-
generated table 
Allocation concealment 
(selection bias) 
Low risk Tablets given to all the groups were visually 
indistinguishable and vials were numbers with 
unique codes. 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk Participants: Blinded 
Dentist/dental technician/dental assistant were not 
described to be blinded. 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk It was not reported whether the assessor was 
masked or not, even though the study was claimed 
to be double-blinded. 
Incomplete outcome data 
(attrition bias) 
High risk 1/45 patients withdrew, but we do not know from 
which arm. Lost to follow-up: Group A: n=6; Group 
B: n=1; Group C: n=3. 
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Selective reporting 
(reporting bias) 
Unclear risk For the Secondary outcomes, no post baseline 
data at 3 or 6 months was available for PD, CAL 
and percentage sites with plaque. 
Other bias Low risk Non-significant 
 
 
 
GAIKWAD 2010 
Methods Study design: Randomised clinical trial 
Trial duration: 3 months 
Trial location: Department of Periodontics, Tatyasaheb Kore Dental 
College, India. 
Participants Number of participants: 50 diabetic individuals with chronic 
generalised periodontitis receiving antidiabetic therapy aged 30 -70 
years. Probing depth of the Test group at baseline was 3.36 ± 
0.35mm while the Control group was 3.34 ± 0.40mm. Clinical 
Attachment Level for Test group at baseline was 3.62 ± 0.50mm while 
that of the Control group was 3.46 ± 0.46mm. 
Intervention group: 25 participants. 
Control group: 25 participants. 
Interventions Intervention: 100mg Doxycycline once daily for 15 days.  
Full-mouth SRP. Periodontal measurements recorded by a single 
Stellenbosch University  https://scholar.sun.ac.za
65 
 
examiner with University of North Carolina 15 probe. No changes to 
diabetes medication or diet during the study. 
Control: No Placebo.  
Full-mouth SRP. Periodontal measurements recorded by a single 
examiner with University of North Carolina 15 probe. No changes to 
diabetes medication or diet during the study. 
Outcomes Primary outcomes: Changes in the circulating glycosylated 
haemoglobin level (HbA1c). 
Secondary outcomes: Reduction in probing depth (PD), Increase in 
Clinical attachment level (CAL). 
Notes No Placebo was given to the control group. 
 
Risk of bias table  
Bias 
Authors' 
judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk 
It was not reported if there was any computer-
generated code allocation. 
Allocation concealment 
(selection bias) 
Unclear risk It was not reported if there was any allocation 
concealment. 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk 
Not reported.  
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Blinding of outcome 
assessment (detection 
bias) 
Unclear risk 
Not reported. 
Incomplete outcome data 
(attrition bias) 
Low risk An attrition of 8 subjects was reported, hence only 
42 subjects completed the study.This is 19% which 
is more than 15% and hence undesirable. 
Selective reporting 
(reporting bias) 
Unclear risk In the case of HbA1c, different sample sizes for 
each treatment group were not given at 4 months. 
Other bias Unclear risk non-significant 
 
 
 
GILOWSKI 2012 
Methods Study design: Randomised controlled trial 
Trial duration: 3 months 
Trial location: Medical University of Silesia, Katowice, Poland. 
Participants Number of participants: 34 type 2 diabetic patients with severe to 
moderate, localized or generalized chronic periodontitis, aged 36 - 68 
years in good physical condition. Diabetes diagnosed at least 6 
months before the study. Presence of at least 14 teeth and a 
minimum of 4 non-adjacent sides with probing depth (PD) of ≥4mm. 
Intervention group: 17 participants 
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Control group: 17 participants. 
Interventions Intervention: 20mg doxycycline hydrochloride three times a day for 3 
months. 
NSPT, full-mouth SRP completed in 1 visit with a combination of 
ultrasonic and hand instruments. Local or topical anaesthesia as 
required. Oral hygiene instruction + tooth brushing, interdental 
flossing or brushing demonstrations. 
Control: NSPT, full-mouth SRP completed in 1 visit with a 
combination of ultrasonic and hand instruments. Local or topical 
anaesthesia as required. Oral hygiene instruction + tooth brushing, 
interdental flossing or brushing demonstrations. 
Outcomes Primary outcomes: Changes in circulating HbA1c and MMP-8 levels 
after therapy, with and without antibiotics. 
Secondary outcomes: CAL and PD were measured but portrayed in 
figures and hence could not be extracted accurately. 
Notes Name of the placebo: Saccharum lactis; PPH Galfarmsp.z.o.o., 
Krakow, Poland 
 
Risk of bias table  
Bias 
Authors' 
judgement Support for judgement 
Random sequence 
generation (selection bias) 
Low risk Block randomization was used but no mention of 
computer-generated randomisation. 
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Allocation concealment 
(selection bias) 
Low risk The assignment of drug containers/drugs did not 
include the investigators in the process. 
Blinding of participants and 
personnel (performance 
bias) 
Low risk Quote: "All study personnel and participants were 
blinded to the treatment assignment for the 
duration of the study". 
Blinding of outcome 
assessment (detection 
bias) 
High risk 
Quote: "The statisticians and data monitoring 
committee saw the unblinded data". 
Incomplete outcome data 
(attrition bias) 
Unclear risk The number of participants for each analysis was 
not ascertainable as it was not stated. 
Selective reporting 
(reporting bias) 
Unclear risk In the case of Secondary outcomes, CAL and PD 
were measured but the data was in figures and 
not numerical tabulations. 
Other bias Low risk Non-significant. 
 
GOLUB, LEE 2008 
Methods Study design: Randomised controlled trial 
Trial duration: 3 months 
Trial location: University of Nebraska Medical Centre College of 
Dentistry and the School of Dental Medicine at Stonybrook University, 
Stoney Brook. (Multi-Centre). 
Participants Number of participants: 128 Osteopenic post-menopausal females 
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with moderate to advanced periodontitis between the ages of 45-70 
years, post-menopausal for at least 6 months and not receiving HRT. 
Good general health without co-morbidities, are having at least 9 
posterior teeth and at least 2 sides with a probing depth of ≥5mm 
together with bleeding on probing, ≥5mm clinical attachment level 
loss and radiographic evidence of alveolar bone height loss. 
Osteopenia of the lumbar spine or femoral neck. 
Intervention group: 64 participants 
Control group: 64 participants. 
Interventions Intervention: 20mg Sub-antimicrobial dose doxycycline, three times a 
day for 2 years. 
Calcium and vitamin D supplements twice daily (a total of 1200mg of 
calcium and 400iu of vitamin. Periodontal maintenance consisting of 
scaling and root-planing every 3-4 months for 2 years. 
Control: 20mg Placebo, three times a day for 2 years. 
Calcium and vitamin D supplements twice daily (a total of 1200mg of 
calcium and 400iu of vitamin. Periodontal maintenance consisting of 
scaling and root-planing every 3-4 months for 2 years. 
Intervention group: 64 participants. 
Control group: 64 participants. 
Outcomes Primary outcomes: Changes in the GCF biomarkers IL-1ß and MMP-
8 levels after therapy, with or without antibiotics. 
Secondary outcomes: n/a (no measurements) 
Notes 
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Risk of bias table  
Bias 
Authors' 
judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk 
Randomization was reported but not described. 
Allocation concealment 
(selection bias) 
Unclear risk Allocation concealment was not reported neither 
described. 
Blinding of participants 
and personnel 
(performance bias) 
Low risk 
Participants were masked; the dentist, dental 
technician and dental assistant were masked. 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk 
It was not reported whether the assessor was masked 
or not. 
Incomplete outcome 
data (attrition bias) 
Low risk 15 participants dropped out of the trial. 2 participants 
dropped out of the control group and 13 participants 
dropped out of the test group. This was 11% which 
was not significant. 
Selective reporting 
(reporting bias) 
Low risk 
All specified outcomes were reported on. 
Other bias Unclear risk Non-significant. 
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GROSSI 1997 
Methods Study design: Randomised controlled trial 
Trial duration: 6 months 
Trial location: Periodontal Disease Research Center, Department of 
Oral Biology, School of Dental Medicine, Buffalo, NY, USA 
Participants Number of participants: 113 participants, 5-arms. 
Patients suffering from moderate to severe periodontal disease with a 
history of diabetes mellitus as per the W.H.O. criteria. Diabetes 
Mellitus, diagnosed with the Haemoglobin A1c test where the HbA1c 
values range from ≥7% at the time of screening while that for severe 
periodontitis was >30% of the sites with ≥5mm clinical attachment 
level (CAL) and ≥2 sites with a probing depth (PD)≥6mm in each 
quadrant that had bleeding on probing (BOP). 
Interventions (TG1) Water irrigant + 100mg Doxycycline=22 
(TG2) 0.12% Chlorhexidine irrigant + 100mg Doxycycline=23 
(TG3) 0.05% Povidone-iodine irrigant + 100mg Doxycycline=23 
(TG4) 0.12% Chlorhexidine irrigant + 100mg Placebo=22 
(TG5) Water irrigant + 100mg Placebo=23 
Group #1: Ultrasonic bactericidal curettage (UBC) performed with 
ultrasonic device with continuous irrigation with WATER solution 
where each tooth was scaled, and root planed. UBC delivered in 2 
sessions, one week apart, half of the mouth treated at each session. 
100mg doxycycline per day was prescribed for 2 weeks from first day 
of treatment. 
Group #2: UBC performed with ultrasonic device with continuous 
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irrigation with 0.12% Chlorhexidine solution where each tooth was 
scaled, and root planed. UBC delivered in 2 sessions, one week 
apart, half of the mouth treated at each session. 100mg doxycycline 
per day was prescribed for 2 weeks from first day of treatment. 
Group #3: UBC performed with ultrasonic device with continuous 
irrigation with 0.05% Povidone-iodine solution where each tooth was 
scaled, and root planed. UBC delivered in 2 sessions, one week 
apart, half of the mouth treated at each session. 100mg doxycycline 
per day was prescribed for 2 weeks from first day of treatment. 
Group#4: UBC performed with ultrasonic device with continuous 
irrigation with 0.12% Chlorhexidine solution where each tooth was 
scaled, and root planed. UBC delivered in 2 sessions, one week 
apart, half of the mouth treated at each session. 100mg Placebo per 
day was prescribed for 2 weeks from first day of treatment. 
Control Group: UBC performed with ultrasonic device with continuous 
irrigation with WATER solution where each tooth was scaled, and root 
planed. UBC delivered in 2 sessions, one week apart, half of the 
mouth treated at each session. 100mg Placebo per day was 
prescribed for 2 weeks from first day of treatment. 
Outcomes Primary outcomes: Changes in circulating glycosylated haemoglobin 
levels (HbA1c). 
Secondary: PD and CAL were measured but the data could not be 
accurately extracted since they appeared in figures and not 
tabulations. 
Notes The name of the placebo was not provided. 
 
Risk of bias table  
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Bias 
Authors' 
judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk 
The method used for randomisation was not stated. 
Allocation 
concealment 
(selection bias) 
Unclear risk 
Not reported. 
Blinding of 
participants and 
personnel 
(performance bias) 
Unclear risk 
No information provided whether the Dentist, Dental 
Technician or Dental assistant was blinded. 
Blinding of outcome 
assessment 
(detection bias) 
Low risk 
Clinical assessor was blinded. 
Incomplete outcome 
data (attrition bias) 
Low risk There was no loss to follow-up. However, 4 patients 
were excluded at analysis stage, 2 patients from the 
iodine/doxycycline group and 2 patients from the 
water/placebo group. The analysis was per-protocol. 
Selective reporting 
(reporting bias) 
Unclear risk The estimates for PD and CAL at 3 and 6 months, are 
not reported in tabular form but in figures, while only the 
baseline estimates are stated in tabular form. 
Other bias Unclear risk Non-significant 
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HAN 2012 
Methods Study design: Randomised clinical trial 
Trial duration: 6 months 
Trial location: Department of Periodontology, School of Dentistry, Ege 
University, Izmir, Turkey. 
Participants Number of participants: 36 participants. 
Systemically healthy patients with severe generalised chronic 
periodontitis in the age range of 35 – 54 years, diagnosed with severe 
generalised chronic periodontitis if they had >30% of the sites with 
≥5mm clinical attachment level (CAL) and ≥2 sites with a probing 
depth (PD) ≥6 mm in each quadrant that had bleeding on probing 
(BOP). CAL was consistent with the amount of plaque accumulation 
or local contributing factors. Presence of 16 or more teeth. 
Intervention group: 18 participants. 
Control group: 18 participants. 
Interventions Intervention: 500mg Azithromycin once daily x 3 days. 
Oral hygiene instruction and full-mouth SRP performed per quadrant 
under local anaesthesia in 4 sequential visits. After SRP, GCF and 
subgingival plaque samples were collected. 500 mg Azithromycin was 
given at the end of the last treatment visit, once daily for 3 days. 
Motivation to reinforce the oral hygiene and maintenance therapy was 
administered at every visit during the study period. 
Control: Oral hygiene instruction and full-mouth SRP performed per 
quadrant under local anaesthesia in 4 sequential visits. After SRP, 
GCF and subgingival plaque samples were collected. 500 mg 
Placebo was given at the end of the last treatment visit, once daily for 
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3 days. Motivation to reinforce the oral hygiene and maintenance 
therapy was administered at every visit during the study period. 
Outcomes Primary outcomes: Changes the GCF MMP-8 levels after therapy, 
with or without antibiotics. 
Secondary outcomes: PD sites in percentage, however, the data from 
baseline to 4 months was incomplete. 
Notes The name of the placebo was not provided. 
 
Risk of bias table  
Bias 
Authors' 
judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk 
Computer-generated randomization list. 
Allocation concealment 
(selection bias) 
Low risk Treatment allocation was concealed by randomization 
list kept by one author and medications distributed by 
another masked author. Medication and placebo in 
identical opaque capsules. 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants: Blinded, Dentist/dental technician/dental 
assistant blinded to the type of pharmacological 
treatment. 
Blinding of outcome 
assessment (detection 
Low risk Outcome assessor was blinded, and Biostatistician 
was masked to treatment assignment for the study 
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bias) duration.  
Incomplete outcome 
data (attrition bias) 
High risk 8 patients were excluded, 4 from each arm due to their 
inability to attend regular maintenance appointments. 
This was a 22% exclusion rate. 
Selective reporting 
(reporting bias) 
Unclear risk In the case of Secondary outcomes, for the PD sites in 
percentage, the data from baseline to 4 months was 
incomplete. 
Other bias Unclear risk Non-significant. 
 
JONES 2007 
Methods Study design: Randomised controlled trial 
Trial duration: 4 months 
Trial location: All 4 Department of Veterans Administration facilities at 
greater Boston, United States of America. (Multi-site study). 
Participants Number of participants: 165 Diabetic veterans with poorly controlled 
diabetes having ≥1 HbA1c values of >8.5% within the last 6 months 
and they had at least 8 teeth and had sufficient periodontal treatment 
need as indicated by the CPITN scores of ≥3 in at least 2 sextants. 
Intervention group: 83 participants 
Control group: 82 participants 
Interventions Intervention: 100mg doxycycline daily for 14 days and chlorhexidine 
gluconate rinses 30cc 0.12% twice daily for 4 months. 
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The intervention was early treatment for 4 months which consisted of 
periodontal scaling and root-planing until smooth root surfaces were 
achieved. 
Control: Early treatment for 4 months which consisted of periodontal 
scaling and root-planing until smooth root surfaces were achieved. 
Usual care was given to the control group and no medications or 
drugs were given to them. 
Outcomes Primary outcomes: Changes in circulating glycosylated haemoglobin 
(HbA1c) in the early treatment versus untreated (usual care) groups 
and percent of participants with decreases in HbA1c. 
Secondary outcomes: Periodontal pocket depth (PPD) sites in 
percentage, however the data from baseline to 4 months was 
incomplete and hence unworkable. 
Notes This is a multi-centre trial. 
 
Risk of bias table 
Bias 
Authors' 
judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk 
The Proc Plan in SAS version 8 software was used to 
obtain 12 blocks of 8 using a seed of 020348. 
Allocation 
concealment 
(selection bias) 
Low risk 
Group assignments were put on a white card and sealed 
in white envelopes and numbered consecutively. 
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Blinding of 
participants and 
personnel 
(performance bias) 
High risk 
Participants were not masked; the dentist, dental 
technician and dental assistant were not masked. 
Blinding of outcome 
assessment 
(detection bias) 
Low risk 
The outcome assessor was blinded. 
Incomplete outcome 
data (attrition bias) 
High risk Out of 193 randomized participants, 28 were excluded 
and 165 were included in the study while 33 persons 
withdrew and finally, 132 participants completed the 
study. The drop-out rate was high. 32% of participants 
never complete the trial. 
Selective reporting 
(reporting bias) 
Unclear risk the secondary outcomes measured were periodontal 
pocket depth (sites in percentage), however, the data 
from baseline to 4 months was incomplete and hence 
unworkable 
Other bias High risk A 5% difference at baseline between Usual treatment 
and Early treatment group with respect to diabetes 
medicines, insulin only. 
 
LOPEZ 2011 
Methods Study design: Randomised clinical trial 
Trial duration: 12 months 
Trial location: Dr. Eloisa Diaz Dental Center, San José Hospital, 
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Santiago, Chile. 
Participants Number of participants: 165 participants with Metabolic Syndrome 
(MetS) having periodontitis, between the ages of 35 – 65 years and 
having retained ≥14 teeth. The diagnostic criteria for periodontitis was 
the presence of ≥4 teeth with  
≥1 sites with probing depth (PD)≥4 mm and concomitant clinical 
attachment loss of ≥3mm.Intervention group: 82 participants. 
Control group: 83 participants. 
Interventions Intervention: 250mg Metronidazole t.i.d AND 500mg Amoxicillint.i.d 
for 7 days. Oral hygiene instructions were given. Supra & Subgingival 
SRP & crown polishing under LA with hand and ultrasonic 
instruments. 
Control: 50mg placebo t.i.d AND 500mg placebo t.i.d for 7 days. Oral 
hygiene instructions were given. Supra & Subgingival SRP & crown 
polishing under LA with hand and ultrasonic instruments. 
Outcomes Primary outcomes: Changes in circulating serum CRP levels. 
Secondary outcomes: PD, CAL and Plaque (percentage of sites), 
however, their depiction in figures could not enable accurate data 
extraction. 
Notes The name of the placebo was not provided. 
 
Risk of bias table  
Bias Authors' Support for judgement 
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judgement 
Random sequence 
generation 
(selection bias) 
Low risk Computer-generated for the first 8 participants enrolled. 
For the remaining participants, the Minimization method 
was used to assign them to the groups. 
Allocation 
concealment 
(selection bias) 
Low risk Allocation sequence generated by a statistician without 
clinical involvement in the study, who also assigned the 
participants to study groups. Medication and placebo 
tablets were identical in appearance, in consecutively 
numbered bottles as per the randomization schedule. 
Treatment assignments concealed by opaque envelopes 
and group allocation revealed to the therapist on the day 
treatment began. 
Blinding of 
participants and 
personnel 
(performance bias) 
Unclear risk 
Participants were masked; the dentist, dental technician 
and dental assistant were NOT masked. 
Blinding of outcome 
assessment 
(detection bias) 
Low risk 
The outcome assessor was masked. 
Incomplete 
outcome data 
(attrition bias) 
Low risk 5 participants were excluded at the final analysis stage, 3 
from the test group, and 2 from the control group. 3% of 
participants did not complete the trial. 
Selective reporting 
(reporting bias) 
Unclear risk In the case of Secondary outcomes, the depiction of the 
data for PD, CAL and Plaque percentage (of sites) in 
figures lead to imprecise data. 
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Other bias Low risk Non-significant. 
 
 
 
MIRANDA 2014 
Methods Study design: Randomised controlled trial 
Trial duration: 1 year 
Trial location: Department of Periodontology, Dental Research 
Division, Guarulhos University, Sao Paulo, Brazil. 
Participants Number of participants: 58 Type 2 diabetic participants with 
generalized chronic periodontitis referred to the dental clinic, aged 35 
years or more. Diagnosed with type 2 DM for 5 or more years. 
Presence of at least 15 teeth. More than 30% of the sites with probing 
depth (PD) and clinical attachment level (CAL) of ≥4mm and a 
minimum of 6 teeth with at least 1 site with PD and CAL ≥5mm and 
bleeding on probing (BoP) at baseline. 
Intervention group: 29 participants 
Control group: 29 participants. 
Interventions Intervention: After 1st SRP session, 400mg Metronidazole+ 500mg 
Amoxycillin three times a day for 14 days. 
Initial supragingival plaque & calculus removal and restorations. Oral 
hygiene instructions given. 4-6 one hour-sessions of SRP with 
manual curettes and ultrasound device under local anaesthesia. 
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Duration of therapy was 14 days. End-point for SRP appointment was 
the confirmation of smoothness of the scaled roots as checked by 
study co-ordinator.  
Control: After 1st SRP session, Placebo was dispensed. 
Initial supragingival plaque & calculus removal and restorations. Oral 
hygiene instructions given. 4-6 one hour-sessions of SRP with 
manual curettes and ultrasound device under local anaesthesia. 
Duration of therapy was 14 days. End-point for SRP appointment was 
the confirmation of smoothness of the scaled roots as checked by 
study co-ordinator. 
Outcomes Primary outcomes: Changes in the circulating glycosylated 
haemoglobin level (HbA1c). 
Secondary outcomes: Reduction in probing depth (PD) and gain in 
clinical attachment level (CAL). 
Notes Name of the placebo was not provided. 
Funding by the São Paulo State Research Foundation, Brazil. 
 
Risk of bias table  
Bias 
Authors' 
judgement Support for judgement 
Random sequence 
generation (selection bias) 
Low risk 
Computer-generated code allocation was used. 
Allocation concealment Low risk Identical plastic bottles containing antibiotics or 
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(selection bias) placebos were coded to conceal assignment. 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants: Blinded, Dentist/dental 
technician/dental assistant blinded to the type of 
pharmacological treatment. 
Blinding of outcome 
assessment (detection 
bias) 
Low risk 
Outcome assessor was blinded. 
Incomplete outcome data 
(attrition bias) 
Low risk Loss to follow-up was described adequately. 2 
participants from control group did not attend 
baseline visit and were excluded. 
Selective reporting 
(reporting bias) 
Low risk The protocol was not available, but all specified 
outcomes were reported on. 
Other bias Low risk Non-significant 
 
O'CONNELL 2008 
Methods Study design: Randomised controlled trial. 
Trial duration: 3 months 
Trial location: Department of Oral Surgery & Periodontology, 
University of São Paulo Ribeiro-Preto, Brazil. 
Participants Number of participants: 30 Type 2 diabetic participants in good 
physical condition and having no additional serious medical 
conditions with periodontitis recruited from 2400 medical records, 
aged 46-70 years. Type 2 diabetes mellitus diagnosed for >5 years 
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and HbA1c>8%. Presence of at least 1 site with probing depth≥5mm 
and 2 teeth with attachment loss≥6mm. 
Intervention group: 15 participants 
Control group: 15 participants 
Interventions Intervention: 100mg Doxycycline once daily for 2 weeks after an initial 
dose of 200mg. 
Pre-SRP antibiotics a day before therapy. A total of 4 sessions within 
24-36 hours using hand instruments and ultrasonic device under local 
anaesthesia. Extraction of unsalvageable teeth. Oral hygiene 
reviewed twice monthly followed by prophylaxis for 3 months. 
Control: Placebo once daily for 2 weeks after initial dose of placebo. 
A total of 4 sessions within 24-36 hours using hand instruments and 
ultrasonic device under local anaesthesia. Extraction of 
unsalvageable teeth. Oral hygiene reviewed twice monthly followed 
by prophylaxis for 3 months. 
Outcomes Primary outcomes: Changes in the circulating glycosylated 
haemoglobin level (HbA1c) and IL-1ß levels. 
Secondary outcomes: Changes in Periodontal probing depth (PD), 
Clinical attachment loss (CAL) and Plaque Index percent reduction 
(PI). 
Notes The name of the placebo was not provided. 
 
Risk of bias table  
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Bias 
Authors' 
judgement Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk The participants that met the inclusion criteria 
were assigned to two groups randomly. 
Allocation concealment 
(selection bias) 
Unclear risk 
Not reported. 
Blinding of participants and 
personnel (performance 
bias) 
Unclear risk 
The trial itself was double-masked, placebo-
controlled. 
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk 
It was not mentioned if the operator was blinded. 
Incomplete outcome data 
(attrition bias) 
Unclear risk Outcome data on subjects who did not complete 
treatment is not mentioned. 
Selective reporting 
(reporting bias) 
High risk All specified outcomes were reported on though 
the researchers did not give separate results for 
the intervention and placebo groups. 
Other bias Low risk Non-significant. 
 
PAYNE, Golub 2011 
Methods Study design: Randomised controlled trial 
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Trial duration: 2 years 
Trial location: University of Nebraska Medical Centre, College of 
Dentistry and Department of Oral Biology & Pathology School of 
Dental Medicine, Stoney Brook University, New York, USA. 
Participants Number of participants: 113 Post-menopausal women with 
osteopenic at lumbar spine or femoral neck, with generalized to 
advanced chronic periodontitis recruited on a rolling admission basis, 
aged 45-70 years. Presence of at least 2 sites with probing depths 
and clinical attachment loss ≥5mm together with bleeding on probing. 
The 2 sites had to be on different posterior teeth. 
Intervention group: 51 participants 
Control group: 62 participants. 
Interventions Intervention: 20mg SDD once daily for 2 years  
Periodontal maintenance therapy over a 2-year period consisting of 
scaling and root-planing. 1200mg Calcium and 400mg i.u. vitamin D 
supplements to be taken twice daily were taken 1 hour after taking 
study drug.  
Control: Placebo once daily for 2 years 
Periodontal maintenance therapy over a 2-year period consisting of 
scaling and root-planing. 1200mg Calcium and 400mg i.u. vitamin D 
supplements to be taken twice daily were taken 1 hour after taking 
study drug. 
Outcomes Primary outcomes: Changes in circulating hs-CRP, IL-6, IL-1ß, MMP-
8 and TIMP-1 after therapy, with or without antibiotics. 
Secondary outcomes: not measured. 
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Notes The name of the placebo was not provided. 
 
Risk of bias table  
Bias 
Authors' 
judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk 
Centrally randomized through a call-in centre. 
Allocation concealment 
(selection bias) 
Unclear risk 
Method of concealment was not stated. 
Blinding of participants 
and personnel 
(performance bias) 
Unclear risk 
Not reported. 
Blinding of outcome 
assessment (detection 
bias) 
Low risk Quote: "Treatment code identifying the SDD and 
Placebo arms were concealed from study 
investigators and statistician". 
Incomplete outcome data 
(attrition bias) 
Low risk Loss to follow-up was described adequately with 13 
participants lost as follows: 
13 subjects withdrew consent (placebo n=2, SDD 
n=10) and 1 subject withdrew due to adverse 
effects (SDD n=1). 11% was the loss to follow-up. 
Selective reporting Unclear risk Secondary outcomes were not reported. 
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(reporting bias) 
Other bias Unclear risk No description given regarding allocation 
concealment. 
 
 
 
REINHARDT 2010 
Methods Study design: Randomised controlled trial 
Trial duration: 3 years 
Trial location: University of Nebraska Medical Centre College of 
Dentistry and the School of Dental Medicine at Stonybrook University, 
Stoney Brook. (Multi-Centre). 
Participants Number of participants: 128 Osteopenic post-menopausal females 
with moderate to advanced periodontitis between the ages of 45-70 
years, post-menopausal for atleast 6 months and not receiving HRT. 
Good general health without co-morbidities, are having at least 9 
posterior teeth and at least 2 sides with a probing depth of ≥5mm 
together with bleeding on probing, ≥5mm clinical attachment level 
loss and radiographic evidence of alveolar bone height loss. 
Osteopenia of the lumbar spine or femoral neck. 
Intervention group: 64 participants 
Control group: 64 participants. 
Interventions Intervention: 20 mg Sub-antimicrobial dose doxycycline (SDD) three 
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times daily for 2 years. 
Periodontal maintenance therapy every 3-4 months over a 2-year 
period consisting of scaling and root-planing. 1200mg Calcium and 
400mg i.u. vitamin D supplements to be taken twice daily were taken 
1 hour after taking the study drug. 
Control: 20 mg Placebo three times daily for 2 years. 
Periodontal maintenance therapy every 3-4 months over a 2-year 
period consisting of scaling and root-planing. 1200mg Calcium and 
400mg i.u. vitamin D supplements to be taken twice daily were taken 
1 hour after taking the study drug. 
Outcomes Primary outcomes: Changes in GCF biomarkers IL-1ß and MMP-8 
after therapy, with or without antibiotics. 
Secondary outcomes: Changes in the relative Clinical Attachment 
Levels (rCAL), however, no baseline values for rCAL were reported. 
Notes The name of the placebo was not provided. 
 
Risk of bias table  
Bias 
Authors' 
judgement Support for judgement 
Random sequence 
generation (selection bias) 
Low risk Computer-generated randomization list which was 
generated in blocks to randomize participants to 
groups. 
Allocation concealment Low risk Treatment allocation was concealed as treatment 
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(selection bias) assignments were given over the telephone. 
Blinding of participants and 
personnel (performance 
bias) 
Low risk 
Participants were masked; the dentist, dental 
technician and dental assistant were masked.  
Blinding of outcome 
assessment (detection 
bias) 
Unclear risk 
It was not reported whether the assessor was 
masked or not. 
Incomplete outcome data 
(attrition bias) 
Low risk 15 participants were excluded. 2 participants 
dropped out of the control group. 13 participants 
dropped out of the test group. 
Selective reporting 
(reporting bias) 
Unclear risk In the case of Secondary outcomes, there were 
no baseline values for the changes in the relative 
clinical attachment level (rCAL). 
Other bias Unclear risk No mention is made whether the telephone call 
was recorded by the call-centre for verification 
purposes. 
 
 
 
 
SALEH 2016 
Methods Study design: Randomised controlled trial 
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Trial duration: 3 months 
Trial location: Oral Health Centre, University of Western Australia, 
Australia. 
Participants Number of participants: 37 participants, 3 arms. 
Adults above the age of 30 and non-smokers, with generalized 
moderate to advanced chronic periodontitis. Good systemic health. 
Minimum of 20 teeth present and minimum of 8 sites with PPD≥5mm, 
CAL≥5mm and bleeding in probing (BOP). Radiographic evidence of 
bone loss of at least ⅓ of root length. 
Intervention #1: Scaling and root planing 
(SRP)+Amoxicillin+Metronidazole=13 
Intervention #2: SRP+Azithromycin=12 
Control group: SRP+placebo=12 
Interventions Interventions: 
Group #1: (Amox+MET): Oral hygiene instructions (OHI) and 
extraction of non-restorable teeth. Periodontal debridement in 2-4 
sessions for each patient under local anaesthetic using hand and 
ultrasonic instruments till the scaled roots displayed smooth surfaces. 
At the end of the scaling and root planing (SRP) sessions, 500mg 
Amoxicillin and 200mg Metronidazole administered every 8 hours for 
7 days. 
Group #2: (AZ): Oral hygiene instructions (OHI) and extraction of non-
restorable teeth. Periodontal debridement in 2-4 sessions for each 
patient under local anaesthetic using hand and ultrasonic instruments 
till the scaled roots displayed smooth surfaces. At the end of the SRP 
sessions, 500mg Azithromycin administered every 8 hours for 7 days. 
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Control Group: (SRP+Placebo): Oral hygiene instructions (OHI) and 
extraction of non-restorable teeth. Periodontal debridement in 2-4 
sessions for each patient under local anaesthetic using hand and 
ultrasonic instruments till the scaled roots displayed smooth surfaces. 
At the end of the SRP sessions, Placebo capsules were administered 
every 8 hours for 7 days. 
Outcomes Primary outcomes: Changes in probing depth (PD) in mm, in clinical 
attachment level (CAL) and plaque index (PI). 
Secondary outcomes: nil 
Notes The name of the placebo was not provided. 
 
Risk of bias table  
Bias 
Authors' 
judgement Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk 
Random assignment by means of a computer-
generated table. 
Allocation concealment 
(selection bias) 
Low risk Participants were divided randomly into 3 colour 
coded groups and a medication corresponding to 
each colour. 
Blinding of participants 
and personnel 
(performance bias) 
Low risk Participants: blinded 
Dentist/Clinician/Assistant: blinded. 
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Blinding of outcome 
assessment (detection 
bias) 
Low risk Quote: "The type of medication corresponding to 
each colour was not revealed until the statistical 
analyses were complete". 
Incomplete outcome 
data (attrition bias) 
Low risk All randomised participants were included in the final 
analysis. 
Selective reporting 
(reporting bias) 
Low risk The protocol was not available, but all outcomes 
were addressed which was set out in the beginning. 
Other bias Low risk Non-significant. 
 
TÜTER 2007 
Methods  Study design: Randomised clinical trial 
Trial duration: 6 weeks 
Trial location: Department of periodontology of Gazi University, Ankara, 
Turkey. 
Participants  Number of participants: 36 participants with both chronic periodontitis and 
coronary artery disease (CAD), and age not > 70 years who had 
angiographically proven CAD. Patients showing radiographic evidence of 
bone loss and attachment loss and those who had a minimum of 6 
periodontal pockets >4mm. 
Intervention group: 18 participants. 
Control group: 18 participants. 
Interventions  Intervention: 20 mg Sub-antimicrobial dose doxycycline (SDD) three times 
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daily for 6 weeks. 
Phase 1 therapy including oral hygiene instruction and SRP under local 
anaesthesia. 2. Full-mouth SRP once a week for 2 weeks by sharp sickles, 
Gracey & universal curettes and ultrasonic instruments. 
Control: 20 mg Placebo, three times daily for 6 weeks. 
Phase 1 therapy including oral hygiene instruction and SRP under local 
anaesthesia. 2. Full-mouth SRP once a week for 2 weeks by sharp sickles, 
Gracey & universal curettes and ultrasonic instruments. 
Outcomes  Primary outcomes: Changes in the GCF levels of MMP-8 and serum levels of 
hs-CRP. 
Secondary outcomes: Plaque index (PI), Pocket probing depth (PD) and 
Clinical attachment loss (CAL). 
Notes  The name of the placebo was not provided. 
 
Risk of bias table  
Bias 
Authors' 
judgement Support for judgement 
Random sequence generation 
(selection bias) 
Unclear risk 
Not described. 
Allocation concealment 
(selection bias) 
Unclear risk 
Not described. 
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Blinding of participants and 
personnel (performance bias) 
Low risk Participants were masked; the dentist, 
dental technician and dental assistant were 
masked. 
Blinding of outcome 
assessment (detection bias) 
Unclear risk It was not reported whether the assessor 
was masked or not. 
Incomplete outcome data 
(attrition bias) 
Low risk All randomized participants were included in 
the final analysis. 
Selective reporting (reporting 
bias) 
Low risk 
All specified outcomes were reported on. 
Other bias Unclear risk Non-significant. 
CHARACTERISTICS OF EXCLUDED STUDIES 
Aljateeli 2014  
Reason for exclusion Surgical procedure as opposed to non-surgical therapy 
 
Ardila 2015  
Reason for exclusion Aggressive periodontitis 
 
Arora 2013  
Reason for exclusion Non-antibiotics in intervention-arm 
 
Arweiler 2014  
Reason for exclusion Aggressive periodontitis 
 
Awartani 1998  
Reason for exclusion Local application of antibiotic gel 
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Bogren 2008  
Reason for exclusion Aggressive periodontitis 
 
Cionca 2009  
Reason for exclusion No relevant biomarkers 
 
D'Aiuto 2005  
Reason for exclusion No systemic antibiotic therapy 
 
Dastoor 2007  
Reason for exclusion Locally delivered antibiotic 
 
Emingil 2012  
Reason for exclusion Aggressive periodontitis 
 
Fiorini 2013  
Reason for exclusion No antibiotics in intervention-arm 
 
Giannopoulou 2016  
Reason for exclusion Periodontal surgery performed in RCT 
 
Goodson 2012  
Reason for exclusion No relevant biomarkers 
 
Graziani 2015  
Reason for exclusion No antibiotics in intervention-arm 
 
Griffiths 2011  
Reason for exclusion Aggressive periodontitis 
 
Guerrero 2014  
Reason for exclusion Aggressive periodontitis 
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Haas 2008  
Reason for exclusion Aggressive periodontitis 
 
Haas 2012  
Reason for exclusion Aggressive periodontitis 
 
Haas 2016  
Reason for exclusion Aggressive periodontitis 
 
Harks 2015  
Reason for exclusion No relevant biomarkers 
 
Khader 2010  
Reason for exclusion No non-surgical periodontal therapy nor scaling and root-planing 
 
Li 2013  
Reason for exclusion No relevant biomarkers 
 
Lopez 1998  
Reason for exclusion No relevant biomarkers 
 
Lopez 2000  
Reason for exclusion No relevant biomarkers 
 
Lopez 2006  
Reason for exclusion No relevant biomarkers 
 
Marcaccini 2010  
Reason for exclusion No antibiotics in intervention-arm 
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Mascarenhas 2005  
Reason for exclusion No relevant biomarkers 
 
Mestnik 2012  
Reason for exclusion Aggressive periodontitis 
 
Miremadi 2014  
Reason for exclusion Surgical procedure as opposed to non-surgical periodontal therapy 
 
Mombelii 2013  
Reason for exclusion No relevant biomarkers 
 
Mombelli 2005  
Reason for exclusion No relevant biomarkers 
 
Mombelli 2015  
Reason for exclusion No relevant biomarkers 
 
Monsarrat 2013  
Reason for exclusion Not an RCT 
 
Oringer 2002  
Reason for exclusion Local delivery of antibiotics 
 
Pourabbas 2014  
Reason for exclusion Photodynamic therapy is not non-surgical periodontal therapy. 
 
Preshaw 2008  
Reason for exclusion No relevant biomarkers 
 
Preus 2013  
Reason for exclusion No relevant biomarkers 
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Preus 2015  
Reason for exclusion No relevant biomarkers 
 
Ramirez 2011  
Reason for exclusion Not an RCT 
 
Renvert 2006  
Reason for exclusion Local delivery of antibiotics 
 
Renvert 2008 
Reason for exclusion Peri-implantitis is not chronic periodontitis 
 
Salminen 2013  
Reason forexclusion No relevant biomarkers 
 
 
 
ADDITIONAL TABLES 
TABLE 4: STUDY PARTICIPANTS AND DIAGNOSTIC CRITERIA FOR INCLUSION 
Study ID Participant status Periodontitis assessment for inclusion 
Almaghlouth 
2013 
Healthy individuals 
without medical 
condition 
Moderate – to - advanced periodontitis. Presence of 
at least 4 teeth with PPD ≥4mm, CAL at least ≥2mm 
and radiographic evidence of bone loss. 
Botero 2013 
Diabetes type 1 or 
type 2 for duration of 2 
years and above. 
Moderate periodontitis Presence of 10 teeth and 
above. CAL ≥4mm, PD of 5mm or more. 
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Engebretson 
2011 
Type 2 diabetes 
diagnosed for 6 
months duration 
CAL ≥5mm 
Gaikwad 2010 
Diabetes disease on 
medication 
Chronic periodontitis with PD 3.36mm, CAL 3.62mm 
Gilowski 2012 
Type 2 diabetes 
diagnosed at least 6 
months before the 
study period 
Periodontitis. Presence of at least 14 teeth and a 
minimum of 4 non-adjacent sides. PD ≥4mm 
Golub 2008 
Osteopenic post-
menopausal women 
not on Hormone 
Replacement Therapy 
(HRT) 
PD ≥5mm, bleeding on probe. CAL ≥5mm with 
radiographic evidence of alveolar bone loss 
Grossi 1997 
Diagnosed with 
diabetes mellitus 
Diabetes Mellitus, diagnosed with the Haemoglobin 
A1c test where the HbA1c values range from ≥7% at 
the time of screening while that for severe 
periodontitis was >30% of the sites with ≥5mm 
clinical attachment level (CAL) and ≥2 sites with a 
probing depth (PD)≥6mm in each quadrant that had 
bleeding on probing (BOP). 
Han 2012 Healthy individuals 
Presence of 16 teeth or more. CAL ≥5mm and PD 
≥2mm with BOP. 
Jones 2007 
Diabetic veterans with 
Hb1c >8.5% in the last 
6 months before the 
Presence of 8 teeth, CPITN >3 in at least 2 sextants 
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trial commenced 
Lopez 2011 
Metabolic Syndrome 
(MetS) Minimum teeth – 14, PD ≥4mm and CAL ≥3mm 
Miranda 2014 
Diagnosed with type 2 
diabetes for more than 
5 years 
Presence of at least 15 teeth, CAL ≥4mm and one 
site of PD and bleeding on probe 
O’connell 2008 
Diagnosed with type 2 
diabetes for more than 
5 years and Hb1c >8% 
PD ≥5mm CAL ≥6mm 
Payne, Golub 
2011 
Post-menopausal 
women with 
osteopenic at lumbar 
spine or femoral neck 
Presence of at least 2 sites of PD and CAL ≥5mm in 
different site of posterior teeth 
Reinhardt 2010 
Osteopenic post-
menopausal women 
not on HRT nor co-
morbidity 
Presence of at least 9 posterior teeth, PD ≥5mm with 
bleeding on probe. CAL ≥5mm and radiographic 
evidence of alveolar bone loss 
Saleh 2016 Healthy participants 
Minimum of 8 sites with PPD ≥5mm and CAL ≥5mm. 
BOP and radiographic evidence of bone loss of at 
least 1/3 of the root of the teeth. 
Tuter 2007 
Angiographic 
diagnosed coronary 
artery disease (CAD) 
PPD ≥4mm with evidence of bone loss 
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Figure 4:    Effects of mechanical debridement combined with antibiotics on biomarkers. 
(Disruption of the inflammatory pathways by periodontal therapy) 
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APPENDICES 
APPENDIX 1 
SEARCH TERMS 
(Medline/PubMed) 
Anti-infective" OR "anti-infective agents" OR “anti-bacterial agents” [MH] OR “systemic 
antibiotics” OR “antibiotic OR "antibiotic therapy”) AND (periodontitis OR “chronic 
periodontitis” OR “periodontal diseases” [MH] OR “periodontitis” [MH] OR Periodontal 
infection). 
The Cochrane Central Register of Controlled Trials (CENTRAL) 
The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library is 
searched using MeSH terms pertaining to periodontitis and Dentistry. CENTRAL consists of 
details of published articles taken from bibliographic databases (MEDLINE and EMBASE 
amongst other databases) and various published and unpublished sources; the Specialised 
Registers maintained by each Cochrane Group consisting of results of the Cochrane 
Collaboration's global hand-searching activities. The search pertaining to the Cochcrane 
Library was as follows: 
ID  SearchHits 
#1MeSH descriptor: [Periodontitis] explode all trees2583 
#2MeSH descriptor: [Chronic Periodontitis] explode all trees681 
#3MeSH descriptor: [Root Planing] explode all trees610 
#4MeSH descriptor: [Dental Scaling] explode all trees1087 
#5MeSH descriptor: [Anti-Bacterial Agents] explode all trees10848 
#6MeSH descriptor: [Biomarkers] explode all trees18369 
Stellenbosch University  https://scholar.sun.ac.za
148 
 
#7MeSH descriptor: [Matrix Metalloproteinase 8] explode all trees62 
#8MeSH descriptor: [Glycated Hemoglobin A] explode all trees5084 
#9MeSH descriptor: [Interleukin-1beta] explode all trees373 
#10MeSH descriptor: [Tissue Inhibitor of Metalloproteinase-1] explode all trees118 
#11MeSH descriptor: [Interleukin-6] explode all trees2811 
#12MeSH descriptor: [Interleukin-8] explode all trees761 
#13MeSH descriptor: [C-Reactive Protein] explode all trees4227 
#14(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR 
#13) in Trials with 'Oral Health' in Cochrane Groups (Word variations have been 
searched)2608; #15Periodont* NOT Photodynamic8882; #16Periodont* NOT 
Topical8550#17Periodontal NOT Laser6042; #18Periodont* NOT Gel8493; #19Periodont* 
NOT Irrigation8724; #20Periodontal NOT release6240; #21Periodontitis NOT 
Aggressive3008; #22Periodontal NOT Flap5702 
#23Periodontal NOT Regeneration5616; #24Periodont* NOT Chlorhexidine8092; 
#25Periodontal NOT Subgingival5512; #26Periodontal NOT Osseous6182; #27Periodont* 
NOT Rinse8588; #28Periodontal NOT surg*3855; #29Periodont* NOT Local7818; 
#30Periodontal NOT toothbrush6052; #31Periodont* NOT pockets8349; #32Periodont* NOT 
antioxidant8965; #33(#14 AND #15 AND #16 AND #17 AND #18 AND #19 AND #20 AND 
#21 AND #22 AND #23 AND #24 AND #25 AND #26 AND #27 AND #28 AND #29 AND #30 
AND #31 AND #32)173; #34Periodont* NOT Instrumen*7786; #35(#33 and #34)149; 
#36Periodont* NOT Alveolar7789; #37(#35 AND #36)134; #38Oral NOT hygiene151504; 
#39(#37 AND #38)113; #40Periodont* NOT pulp*8736; #41(#39 AND #40)111; 
#42Periodont* NOT Fluoride8575; #43(#41 AND #42)108; #44Periodont* NOT 
probiotic*8969; #45(#43 AND #44)105; #46Periodont* NOT diet*8846; #47(#45 AND 
#46)100; #48Periodont* NOT fib*8591; #49(#47AND #48)93; #50Periodont* NOT 
disinfect*8877; #51(#49 AND #50)91; #52Periodont* NOT lesions8623; #53(#51 AND 
#52)90; #54Periodont* NOT meloxicam9036; #55(#53 AND #54)88; #56Periodont* NOT 
flurbiprofen9006; #57(#55 AND #56)85; #58Periodont* NOT relationship8750; #59(#57 AND 
#58)76; #60Periodont* NOT calcium8662; #61(#59 AND #60)75 
 
Appendix 2: Data extraction form for mechanical debridement combined with 
antibiotics in the treatment of periodontitis: effect on systemic biomarkers 
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Review ID: Study ID: Reference ID: 
Person extracting data and date Date of date extraction: Year of study publication: 
Title: 
Author: Publication type:Full text / Abstract / Book chapter/ 
progress report / others. 
Country: 
Checked by: 
 
Participants and setting: 
Describe setting:  
Inclusion criteria: 
Exclusion criteria: 
PARTICIPANTS 
Were the participants patients diagnosed with chronic periodontal disease? 
Describe participants: 
 
Intervention: 
Were comparison groups treated with pre-specified 
 Intervention in one group and control intervention in the other group?  
Study design 
Type of study design (cluster RCT; block randomisation; stratified randomisation; multi-arm; factorial 
etc): 
Unit of randomisation: 
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Experimental intervention: 
Type of intervention: 
Need to clearly describe what the intervention was all about 
 
Comparison 
Type of control used:Active/ No therapy 
Need to clearly describe what the control was all about 
Balanced between treatment 
arms?  
 Yes / No 
OUTCOMES ASSESSED: 
Definition of outcome 
assessed: 
Primary outcomes 
Secondary outcomes 
Outcome not specified: 
 
 
 
 
 
REASONS FOR EXCLUSION OFSTUDY FROM REVIEW ACCORDING TO PROTOCOl 
Method  No RCT / Others 
Participant related   
Outcomes  
Others:   Duplication, e.t.c 
TRIAL CHARACTERISTICS 
Sample size: Study design: 
No. randomized:        No excluded: Funding: 
Recruitment method:  
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Length of follow-up =   from ---- to ----- Conflict of interest statement: 
No. of drop out = 
Reasons for drop out: 
Loss to follow up symmetric in both arms? 
 
Study methods - Risk of bias 
Adequate sequence generation 
Was the allocation sequence 
adequately generated? 
 
Describe: 
Low / High risk / 
Unclear  
 
Allocation concealment 
Was allocation concealment 
adequate? 
 
Describe:     
Low / High risk / 
Unclear 
 
Blinding 
Was knowledge of the allocated 
intervention adequately prevented 
during the study? 
 
Participant: 
Dentist/ Dental technician / Dental 
assistant: 
Outcome assessor: 
Describe: 
Low / High risk 
/Unclear  
 
Low/ High risk / 
Unclear 
 
Low / High risk 
/Unclear 
Incomplete outcome data 
addressed  
Were complete outcome data 
adequately addressed? 
 
Low/Unclear / High risk 
Describe any loss of participants to follow-up at each data 
collection point:                                                              
Describe any exclusion of participants after randomisation: 
Was the analysis intention to treat? If not has the data been able 
to be re-included 
Free of selective reporting bias 
Are reports of study free of 
suggestions of selective reporting 
bias?  
Low risk/ Unclear / High risk 
Describe:     
Need to say whether the protocol of the study was available or 
not and whether all pre-specified outcomes were addressed 
Free of other bias 
Was the study apparently free of 
other problems that could put it at 
Low risk / Unclear /High risk 
If the study was stopped early, explain the reasons: 
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high risk of bias? 
 
Funding 
Describe any baseline imbalance: 
Describe any differential diagnosis: 
 
ADDITIONAL INFORMATIONS 
Were withdrawals described?    Yes     No  Not clear   
Discuss if appropriate………………………………………………………………………………… 
Outcomes for main analysis 
 
Outcome Measures (Dichotomous) 
Total number of participants in study = 
 
Intervention group  
Total no. in study = 
Control group 
Total no. in study = 
Event
s 
Total Events Total 
 Primary outcomes:     
Secondary outcomes:     
Number of participants entering trial  
15% or fewer excluded  
More than 15% excluded  
 Analysed as ‘intention-to-treat’  
Unclear  
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Outcomes for sub-group analyses 
 
 
Outcome Measures (Dichotomous) 
Total number of participants in study = 
 
Intervention group  
total no. in study = 
Control group 
Total no. in study = 
events Total events total 
 Primary:      
Secondary:     
 
Outcome Measures (Continuous)   
Total number of participants in study = 
Intervention group  
Total no. in study = 
Control group 
Total no. in study = 
total mean       
SD 
total mean       SD 
Primary:     
Secondary:     
 
Outcome Measures (Continuous)   
 
Unit of 
measurement 
Total number of participants in study 
= 
 
Intervention 
group  
Total no. in study = 
Control group 
Total no. in study = 
total mean       
SD 
total mean       
SD 
 Primary:       
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Appendix 3: Assessment of risk of bias in the included studies 
(1) Random sequence generation (checking for possible selection bias) 
For each of the included trials, the method used to generate the allocation sequence to 
facilitate an assessment of whether it should produce comparable groups was described in 
detail. 
The method was assessed as: 
• Low risk of bias (a truly random process, e.g. random number table; computer random 
number generator); 
• High risk of bias (a non-random process, e.g. odd or even date of birth; clinic or 
hospital record number); 
• Unclear risk of bias (the process was deemed as such when the method used was not 
described clearly) 
 
(2) Allocation concealment (checking for possible selection bias) 
For each of the included trials, the method used to conceal allocation to interventions prior to 
assignment was described, and it was assessed whether the intervention allocation could 
have been foreseen prior to recruitment, during recruitment or changed after assignment. 
The method was assessed as: 
Secondary:  
General conclusions 
Brief summary of study authors’ main findings/conclusions: 
Notes: 
Exclusion after data extraction: 
Reasons for exclusion: (study design? participants? interventions/ outcomes? attrition? bias?) 
Dates:Date data was extracted and by whom?Date checked and by whom? 
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• Low risk of bias (e.g. telephone or central randomisation; consecutively numbered 
opaque sealed envelopes); 
• High risk of bias (open random allocation; non-opaque or unsealed envelopes, 
alternation; date of birth); 
• Unclear risk of bias (method of allocation not clearly or explicitly stated) 
 
(3.1) Blinding of participants and personnel (checking for possible performance bias) 
For each included trial, blinding was described in terms of the methods used to blind the 
study participants and personnel from the knowledge of which intervention a participant 
received. Studies were deemed as low risk of bias if they were blinded, or alternately, we 
judged that the lack of blinding would have a negligible effect on the results. Blinding was 
assessed separately for different outcomes. 
The methods of blinding were assessed as: 
• Low, high or unclear risk of bias for participants 
• Low, high or unclear risk of bias for personnel 
 
(3.2) Blinding of outcome assessment (checking for possible detection bias) 
For each included trial, the methods used were described in terms of blinding of the outcome 
assessors from the knowledge of which intervention a participant received.  Blinding was 
assessed separately for different outcomes as: 
• Low, high or unclear risk of bias 
(4) Incomplete outcome data (ascertaining any possible attrition bias due to the 
amount, nature and handling of incomplete outcome data) 
For each included trial, and for each outcome, the completeness of data including attrition 
and exclusions from the analysis was described. Attrition and exclusions if any were reported 
and the numbers in the analysis at each stage (as compared to the total randomised 
participants), reasons for attrition or exclusion were reported, and there was a balance across 
groups regarding missing data or were related to outcomes. 
 
The methods to ascertain incomplete outcome data were assessed as: 
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• Low risk of bias (e.g. no missing outcome data; missing outcome data balanced across 
groups); 
• High risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; 
considerable deviation from the intervention received from that assigned at 
randomisation but reported ‘as treated’); 
• Unclear risk of bias. 
 
(5) Selective reporting (checking for reporting bias) 
For each included trial, selective reporting was described in terms of how we investigated the 
possibility of selective outcome reporting bias and what we established. 
The methods to ascertain selective reporting were assessed as: 
• Low risk of bias (here, all of the pre-specified outcomes of the study and all expected 
outcomes of the review were reported); 
• High risk of bias (here, not all the pre-specified outcomes of the study were reported; 
one or more reported primary outcomes were not pre-specified; incomplete reporting 
of outcomes of interest and hence the information rendered unreliable; failure to 
include results of a key outcome in the study that would have otherwise been 
reported); 
• Unclear risk of bias (no clear description or explanation was given regarding the 
outcomes) 
 
(6) Other bias (checking for bias due to problems not covered by 1 to 5 above) 
For each included trial, any important concerns regarding other possible sources of bias were 
described. 
Each study was assessed whether free from other problems that could put it at risk of bias as: 
• Low risk of bias; 
• High risk of bias; 
• Unclear whether there is risk of other bias. 
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(7) Overall risk of bias 
Judgments were pronounced as to whether studies were at high risk of bias as per the criteria 
in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2008). 
Regarding (1) to (6) above, the magnitude and direction of the bias was assessed and 
whether these findings were likely to impact on the findings were contemplated. 
 
 
Appendix 4:Study Protocol 
Mechanical debridement combined with 
antibiotics in the treatment of periodontitis: 
effect on systemic biomarkers.                                  
A Systematic Review. 
 
Background 
Periodontal disease is one of the most common public health concerns worldwide, constituting the 
main cause of tooth loss in adults, prevalent in 5-15% of most populations [1]. Chronic periodontitis is 
a highly prevalent inflammatory disease that affects the periodontium. Although the prevalence of the 
disease varies in different countries, it can be estimated that, in the USA, about 50% of the adult 
populationabove 30 years of age present some form of periodontitis, ranging from mild to 
severe[2].According to a systematic review by Kassebaum et al. (2010), severe chronic periodontitis 
(SP) was the 6th most prevalent non-communicable disease (NCD) in the world, affecting 10.8% of the 
population (Uncertainty Interval [UI]: 10.1% - 11.6%) or 743 million people across the globe [3]. In 
addition, prevalence of SP increased with age, revealing a steep increase between the 3rdand 4th 
decades of life, with a spike in incidence around the age of 38. At the age of 40, the prevalence of SP 
had reached its peak [3]. 
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The etiology of periodontitis is complex and includes the presence of specific pathogens, such as 
Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans and Prevotella intermediain in a 
susceptible host [4].Potential risk factors that increases the odds ratio for periodontitis include tobacco 
use [5], diabetes [6], unhealthy diet [7], genetic factors [8], stress [9] and excessive alcohol 
consumption [10].Central to the disease process of periodontitis is the formation of biofilm on tooth 
and root surfaces, which triggers the immune system. The inflammatory host response affects the 
tissues surrounding the teeth, resulting in destruction of the periodontal apparatus [11]. In its advanced 
stage, periodontitis can lead to difficulty in mastication and speech and can adversely affect 
generalwell-being and quality of life [12]. The diagnosis of periodontal disease is based on clinical 
measures of inflammation, such as bleeding on probing, pocket probing depth and attachment loss, as 
well as radiological evidence of bone destruction [13].  
The effects of periodontitis seem to go beyond the local oral tissues, affecting the systemic 
environment[14,15]. A number of studies have suggested an association between certain NCDs, 
socioeconomic status (SES), adverse pregnancy outcome and periodontal infection (Lalla 2011, 
Gomes-Fihlo 2010, Tonetti (2013)[16,17,18]. Additionally, periodontitishas been associated 
withcertainconditions, such as heart disease [19], diabetes [52,53,54,55], respiratory disease [20] and 
systemic inflammation[21,22]. 
Periodontal treatment entails the elimination of biofilm and microbial deposits from the root surfaces in 
order toreduce the inflammatory host response and tissue destruction[23,24]. Although there are 
several treatment approaches for periodontitis, conservative mechanical debridement (scaling and root 
planing [SRP]) hasbeen the most common therapy [25].Depending on theseverity of inflammation; 
mechanical debridement combined with systemic antibiotics has been advocated as a treatment option. 
There is currently insufficient scientific evidence to support or refute whether systemic antibiotics 
effectively enhance the results of mechanical periodontal treatment[26,27,28,29,30,31]. 
Description of the intervention and how the intervention might work 
Previous meta-analysis [32,33,34]and systematic reviews [35,36,37] have looked at the benefits of 
antimicrobial agents in providing systemic clinical benefit. Systemic antibiotic therapy is effective in 
reaching microorganisms which are otherwise inaccessible to scaling instruments and local antibiotic 
therapy [38]. SRP alone (without adjunctive antibiotics) have been shown to reduce the risk for 
cardiovascular disease (CVD) and diabetes mellitus by improving plasma levels of inflammatory 
(CRP, IL-6, TNF-α) and metabolic (HbA1c) markers of endothelial function [39]. 
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Several molecules have been identified as potential biomarkers for periodontal disease, including 
proteins, cytokines, receptors and enzymes. These biomarkers have been identified and measured in 
the gingival crevicular fluid (GCF), which provide information on the local periodontal destruction, in 
serum and saliva. In saliva, high levels of matrix metalloproteinase (MMPs, including MMP-8, MMP-
14 and TIMP-1) have been associated with periodontitis [40]. Marcaccini et al. reported that salivary 
MMP-8 and MMP-9 can be used as indicators of periodontal treatment response. Systemically, serum 
or blood biomarkers have been associated with periodontal disease; C-Reactive protein (hs-CRP) and 
inflammatory cytokines in serum have been linked to periodontitis [41]. Periodontitis leads to the 
production of local inflammatory mediators which enter the systemic circulation, thus causing an 
inflammatory burden [42]. An increase in the serum C-reactive protein (CRP) levels is indicative of the 
inflammatory burden, as seen in periodontitis patients [43,44,45,46,47,48]. Simultaneously, bacteria 
and their products enter the systemic circulation causing an infectious burden [42]. Circulating oral 
bacteria stimulate hepatocytes to secrete CRP [49,50,51]. Increased levels of CRP associated with 
periodontitis results in insulin resistance and subsequent impaired control of blood glucose in type 2 
diabetes mellitus (DM2) [52,53,54,55], which in turn increases the levels of HbA1c [56,57]. 
The most studied inflammatory biomarkers in relation to periodontitis are: 
1. Matrix Metalloproteinase (MMPs) 
2. Tissue Inhibitors of MMPs (TIMPS) 
3. Cytokines/Interleukins (IL-1β, IL-6 & IL-8) 
4. C-Reactive Protein (CRP) 
5. Glycosylated Hemoglobin (HbA1c) 
 
TNF-α is a cytokine, which has been omitted from the review, as it exhibits an early rise and 
fall after an inflammatory stimulus, being an unstable biomarker, with very low basal levels 
that escape most commercial detectionassays [58]. 
 
Matrix Metalloproteinase (MMPs) 
MMPs are a group of proteolytic enzymes that play an important role in the degradation of collagen 
and extracellular matrix in conditions such as osteoarthritis, tumour cell invasion, rheumatoid arthritis 
and autoimmune skin lesions [59]. In the periodontal disease process, fibroblasts, neutrophils, 
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macrophages, keratinocytes and endothelial cells can produce MMPs. MMP-8 is a significant 
biomarker in periodontitis, also known as collagenase-2 or neutrophil collagenase. 
 
Tissue Inhibitors of MMPs (TIMPs) 
TIMPs are endogenous tissue regulators of MMP activity. A variety of cells produce TIMPs, including 
endothelial cells, fibroblasts, macrophages and keratinocytes [59]. In periodontitis, the TIMPs and 
MMPs proportion is disturbed/skewed toward higher levels of MMPs [60].  TIMPs have an inhibitory 
effect on MMP-8 and MMP-9, enzymes which predominantly breaks type-1 collagen in periodontitis.  
Cytokines 
Cytokines are a group of proteins released in response to an activating stimulus and they function 
through binding to specific cellular receptors [61], being produced by a variety of cells in the human 
body[59]. Interleukins are among the cytokines that seem to be linked to the inflammatory response 
seen in chronic periodontitis [62]. 
 
Interleukin-1β (IL-1β) 
IL-1β is responsible for bone resorption and has an inhibitory effect on bone formation. It stimulates 
prostaglandin synthesis and facilitates the up-regulation of inflammatory response [63]. 
Patients suffering from periodontitis have increased IL-1β levels, which can be measured in the GCF as 
well as in the periodontal tissues. The IL-1β functions as a biomarker for periodontal destruction. 
Studies have found a correlation between levels of IL-1β and the severity of periodontitis [64]. 
Interleukin-6 (IL-6) 
IL-6 is a pro-inflammatory cytokine, which regulates the host response to tissue injury, inducing 
formation of CRP [65]. Together with IL-1, IL-6 facilitates tissue destruction by elevating the MMP 
levels [66]. 
IL-6 is produced by monocytes, vascular endothelial cells, osteoblasts and fibroblasts in reaction to 
inflammatory challenges [67]. They promote immunoglobulin production by plasma cells and are co-
stimulators of T-cell activation [68]. In periodontitis, initial host response is part of the acute-phase 
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response initiated by the activation of fibroblasts, endothelial cells and local macrophages, which lead 
to the release of the TNF-α, IL-6 and IL-1β mediators [69]. 
Interleukin-8 (IL-8) 
IL-8 is a constituent of the IL-8 supergene family. It is able to recruit and activate polymorphonuclear 
neutrophils (PMNs), reason why it has also been linked to inflammation [70]. Lagdive et al. (2013) 
have found that high levels of IL-8 in the GCF of adult patients correlated with destruction of the 
periodontal tissues. 
C-Reactive Protein (CRP) 
CRP is produced by the liver and considered as a biomarker for several conditions, such as 
inflammatory disorders, osteomyelitis, systemic inflammation, neoplasms, vasculitis and rheumatoid 
arthritis [71]. High sensitivity CRP (hsCRP) is able to estimate cardiac and transient ischaemic attack 
(TIA) [71]. Several studies support the finding of high levels of serum CRP in patients with 
periodontitis [71]. DanisiaHabaet al. (2011) proposed that the higher levels of CRP in chronic 
periodontitis patients could make them more susceptible to cardiovascular disease [67]. 
Glycated Haemoglobin (HbA1c) 
Diabetes Mellitus is one of the most studied risks factors for periodontal disease. Studies have reported 
that poor glycaemic control is correlated with higher risk for periodontal disease [49]. It has been 
suggested that there is a 2-way relationship between glycaemic control and periodontal disease [72]. 
Improvement in glycaemic control seems to decrease the risk for periodontitis while periodontal 
treatment might improve glycaemic levels in type 2 diabetes mellitus patients [73]. Glycaemic control 
is the most important factor in the prevention of diabetes complications. Glycated haemoglobin 
(HbA1c) is used as an indicator of serum glucose levels during the 4-month life-cycle of the red blood 
cell, thus being a surrogate marker for glycaemic control [74].  
Periodontal therapy without antibiotics 
There are numerous studies illustrating the positive effect of SRP alone on systemic biomarkers.  Good 
glycaemic control seems to be a pre-requisite for mechanical debridement to have a decreasing effect 
on HbA1c in periodontitis patients with type 2 diabetes mellitus [75,76,77,78].A number of 
ramdomized clinical trials (RCT) have demonstrated the efficacy of mechanical debridement in 
decreasing HbA1c levels in blood [79,80,81,82,83,84,85,86,87,88]. Regarding MMP-8 levels, a study 
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showed that salivary MMP-8 decreases after mechanical debridement [89]. As for IL-1β, four studies 
have confirmed the efficacy of SRP in reducing salivary IL-1β levels [89], blood/circulating IL-1β 
[90,91] and GCF IL-1β levels [92]. The GCF levels of TiMP-1 have also shown a decrease after 
mechanical debridement [93]. 
Amongst the RCT’s evaluating IL-6 levels, four studies revealed a decrease in circulating/blood IL-6 
levels [86,94,95] and GCF IL-6 levels [92] after mechanical debridement. With regardsto IL-8, three 
studies demonstrated a decrease in salivary IL-8 levels [89], GCF IL-8 levels [96] and circulating IL-8 
levels [86]. Ten RCT studies demonstrated a decrease in blood CRP levels after mechanical 
debridement/SRP alone [77,82,83,94,95,97,98,99,100,101]. 
Periodontal therapy with antibiotics 
Mechanical debridement together with doxycycline antibiotics [or sub-antimicrobial-dose doxycycline 
(SDD)] has been shown to decrease the HbA1c levels in blood biomarkers in type 2 diabetes mellitus 
[31,102,103,104,105,106,107,108,109,110,111]. 
Regarding TIMP-1, in one study, SDD was able to down-regulate gingival crevicular fluid (GCF) 
levels of EMMPRIN, which is an up-regulator of MMP’s, and this was associated with increased 
TIMP-1 levels [112]. Reports also suggest that doxycycline associated with non-surgical periodontal 
treatment (NSPT) increasedGCFTIMP-1 levels [113,114]. Lower IL-6 levels have been reported in 
both GCF[30,114] and serum[31,115] after NSPT and antibiotic therapy. GCF MMP-8 levels have also 
shown a reduction in many studies on SRP combined with antibiotics [103,105,114,116,117,118]. 
Reduced serum CRP and IL-1βlevels have also been associated with NSPT combined with SDD 
[115,119,120,121,122]. Lastly, salivary IL-8 levels decreased after SRP and antibiotic therapy [123]. 
Various antibioticsused in the treatment of periodontitis 
A wide variety of systemic antibiotics have been used in the treatment of periodontitis.  The most 
widely used are: Amoxicillin (AM), Azithromycin (AZ), Clarithomycin (CLAR), Doxycycline (DOX), 
Metronidazole (MET), Moxifloxacin (MOX), Ornidazole (ORN) and Clavulanate (CLAV).  AM 
combined with MET is the most popular combination in the treatment of periodontitis [124]. 
WHY IT IS IMPORTANT TO DO THIS REVIEW 
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Diabetes mellitus and cardiovascular diseases are among the systemic diseases that have huge 
economic burden worldwide. Periodontal treatment has been shown to reduce glycaemia and lower 
HbA1c levels in diabetic patients[76,106,107,125,126]. Meta-analyses also support a positive effect of 
periodontal treatment on glycaemic control [127,128]. 
The potential benefit of periodontal therapy on glycaemic control can have major implications on a 
country’s economics. In their study on type1 and type2 diabetes, Brod et al. (2016) pointed out that the 
annual costs per person for missed work-time due to post-prandial hyperglycaemia (PPH) was Euro 
394.78 in Germany (given Euro 8.48 per week; 40 work weeks), £396.83 in the UK (given £8.62 per 
week; 46 work weeks) and U$606.30 in the USA (given U$13.05 per week; 47 work weeks) [129]. 
With regards to cardiovascular diseases (CVD), periodontal therapy has been shown to reduce the risk 
for CVD by improving plasma levels of inflammatory, thrombotic and metabolic markers 
[29,39,97,99] and changing the systolic blood pressure [130]. In addition, periodontal therapy 
normalized haematological markers levels in CVD sufferers [101] and reduced low grade systemic 
inflammatory markers and lipid profile [131]. Researchers have reported that the direct costs of CVD 
were a cumulative U$272 Billion for the USA [132], with an annual estimate of 106 Billion Euros for 
the European Union [133]. A plethora of studies have declared the benefits of periodontal therapy on 
the reduction of CRP levels, which is directly related to cardiovascular health. These findings, if 
proven to be conclusive, can translate into a substantial reduction in the economic burden of diabetes 
and CVD. 
Reasons for excluding Aggressive Periodontitis from the systematic review 
Chronic periodontitis is characterized by periodontal tissue destruction which is commensurate with 
local factors while the progression ranges from slow to moderate. In aggressive periodontitis, there is a 
rapid rate of attachment loss in systemically healthy patients. The scale of tissue destruction is 
disproportionate to the amount of plaque and calculus [134]. 
(1) Genetics 
Studies have shown that very few subgingival bacterial species differed between chronic and 
aggressive periodontitis patients [135], which has led to studies on genetic predisposition [136] and 
familial patterns of disease [137,138,139] as potential risk factors for aggressive periodontitis.  
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(2) Local Risk Factors 
In aggressive periodontitis, there is a lack of relationship between local etiologic factors and the 
amount of periodontal destruction [137]. In contrast, in chronic periodontitis, local factors play a major 
role [140]. 
 
(3) Rate of Bone Loss 
In aggressive periodontitis, the rate of bone loss has been described as being3-4 time higher than the 
rate of progression of chronic periodontitis [137,141]. 
 
To sum-up, though aggressive periodontitis and chronic periodontitis share common disease 
manifestations and outcomes, they are likely to represent two distinct disease categories with 
differences with regards to disease progression, underlying causes and risk factors.  
Reasons for excluding studies evaluating local antibiotics 
Several reviews on local antibiotics in the form of antimicrobial irrigants [142,143,144], chlorhexidine 
chips [145] and subgingival chlorhexidine gel [146] have shown ineffective results.  Magnusson et al. 
(1998) reported little long-term efficacy of antimicrobial irrigants [142], while Cosynet al. (2006) 
reported limited and conflicting results [145]. Nagarakanti et al. (2015) stated that evidence was 
insufficient regarding potential benefits of subgingival irrigation [143]. Gjermo et al. (1993) reported 
that subgingival antibacterial agents have no effects on periodontitis [144]. In their review,Cosyn et 
al(2005)concluded that subgingival chlorhexidine gel administration was not a justified treatment 
[146]. In contrast, a review (Jepsen et al. 2000) showed additional pocket depth reduction and 
attachment gain associated with local antimicrobials [147]. Hussein et al. (2007) also reported 
improved clinical outcomes with the use of locally delivered antibiotics [148]. Since the majority of 
studies have not been able to confirm the efficacy of local antimicrobials in the treatment of 
periodontitis, their application has been excluded from the current review. 
OBJECTIVES 
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To assess the effectiveness of systemic antibiotics as an adjunctive therapy to mechanical treatment in 
the improvement of inflammatory systemic biomarkers as compared to mechanical debridement alone 
in chronic periodontitis. 
Methods 
Criteria for considering studies for this review 
Types of studies 
RCT’scomparing adjunctive systemic antibiotic plus mechanical debridement with mechanical 
debridement alone (scaling and root planing, oral hygiene and prophylaxis). 
Types of participants 
The participants will be individuals diagnosed with chronic periodontal disease. Subjects diagnosed 
with systemic disease, such as diabetes mellitus, cardiovascular diseases, chronic obstructive 
pulmonary disease or chronic kidney disease (minimum 18 years and above), and chronic periodontitis 
will also be included 
Types of interventions 
All interventions that included mechanical debridement combined with adjunctive systemic antibiotics. 
Comparison: Mechanical debridement alone or placebo or no treatment 
Types of outcome measures 
Primary outcomes 
The primary outcomes were changes in serum/blood levels of inflammatory biomarkers (e.g. MMPs, 
TIMPs, Cytokines, CRP and HbA1c)before and after mechanical periodontal treatment with and 
without systemic antibiotics.  
Secondary outcomes 
Changes in the following indices before and after mechanical periodontal treatment with and without 
adjunctive antibiotics: gingival index, plaque index, pocket depth and marginal recession.  
Microbiological outcomes and adverse events were recorded as reported in each study. 
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Search methods for identification of studies 
Electronic database search will be combined with journal hand searching. Attempts will be made to 
identify unpublished and grey literature.  RCTs published in English from 1980 to 2016 will be 
considered. 
Electronic searching 
The following databases were searched for relevant trials: 
Cochrane Oral Health Group’s Trials Register 
CENTRAL – Cochrane Register of Controlled Trials (of the Cochrane Library – current issue) 
MEDLINE (1966 to present), EMBASE (1982 to present) 
The search strategy for MEDLINE using PubMed software formed the foundation for the basic search 
strategy. Cochrane sensitive search filters for identifying RCTs were used. 
Hand searching 
Articles published prior to 1991 will be hand searched since no indexing terms for randomized trials in 
MEDLINE existed [149].Allarticles in parts of journals (supplements and conference abstracts) which 
were not routinely indexed in databases such as MEDLINE will be searched, reference lists of the 
included studies will be screened for additional relevant studies. We will contact experts in the field of 
oral health care to identify any additional published or unpublished trials. We will not apply any date 
or language restrictions. 
Data Collection and analysis 
Selection of studies 
Two review authors, will independently screened the titles and abstracts of the search output to identify 
and select potentially eligible studies. Applying eligibility criteria using a pre-designed eligibility form 
based on the inclusion criteria, duplicate studies and studies that were not relevant to the review will be 
excluded. Full-text articles of potentially relevant studies will be retrieved, and disagreements will be 
resolved through discussion by consulting a third review author. The reference lists for the included 
studies will be screened for additional studies. 
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Data Extraction and Management 
Data extraction form will bedesigned for extraction of relevant information. For eligible studies, two 
review authors will extract data using the data extraction form.  
For each outcome, we will extract the arithmetic means and standard deviations (or information to 
estimate the standard deviations). We will resolve discrepancies through discussion or, if required, 
wewillconsult the third author.Wewillcheck for accuracy and when information regarding any of the 
above is unclear, we will contact authors of the original reports to provide further details. 
Study quality assessment 
Two review authors (SM and ET) will independently and in duplicate performed a quality assessment 
of the included studies. All trials that met the inclusion criteria will be assessed on four major criteria: 
randomization method, concealment of allocation, blinding of patients and care providers, and accurate 
description of withdrawals and drop outs rate 
Kappa statistics will be used to assess the initial agreement between the review authors. Any 
disagreements between the review authors will be resolved by consensus.  
Quality criteria, the definition thereof will be based on guidelines from the Cochrane Handbook for 
Systematic Reviews of Interventions. 
Assessment of Risk of Bias in included studies 
Risk of bias for each study will beassessed independently by the 2 review authors (SLM and ET) using 
the criteria outlined in The Cochrane Handbook for Systematic Reviews of Interventions [150]. The 
method for allocation sequence generation, the completeness of the outcome report, selective reporting 
and any other source of bias that can put a study at high risk of bias will be assessed. Any 
disagreements will be resolved by discussion or by consulting the 3rd assessor. 
Measures of Treatment Effect 
The effect size will be estimated and reported as mean difference (MD), and the 95% confidence 
interval (CI) will be calculated. In cases of inter-study heterogeneity, Random Effects Model will be   
used. If the pooled effect is significant, then pwasto be<0.05. 
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Raw data (i.e. Means, SDs and sample sizes), point estimates (in block display) and CI’s (in line 
displays) will be presented in the form of Forest Plots. 
Heterogeneity Statistic (I2), total number of participants per group, overall average effect (Z-statistics 
and MD statistics) in the random effects model and percentage weight given to individual studies will 
be appended to the Forest Plot. 
Dealing with Missing Data:  Levels of attrition will be noted in the included studies. Sensitivity 
analysis will be used to explore the effect of including studies with high levels of missing data in the 
overall assessment of treatment effect. 
Intention-to-treat analysis will be used, hence all participants randomized to each group in the analyses 
will be included and all participants will beanalyzed in the group to which they were allocated to, 
irrespective of them receiving the allocated intervention or not. For each outcome in each trial, the 
denominator will be the number of randomised minus any participants whose outcomes were missing. 
Assessment of Heterogeneity  
Heterogeneity will beassessed using the chi-squared-based Q-statistic method and the I2 measurement 
with significance indicated by p<0.1. 
Heterogeneity between studies will be explored, quantified and controlled by way of subgroup 
analysis. 
Patient characteristics 
• Self-reported smoking status 
• Initial pocket probing depth 
• Immunological disease (HIV) 
• Patient adhered plaque control 
 
Treatment characteristics 
• Class of antibiotics 
• Baseline and follow-up time 
• Number of sessions for debridement 
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• Supportive follow-up care 
 
Other sources of heterogeneity identified during the review were regarded as post-hoc analysis. 
Sensitivity analysis will be performed, and studies classified as high risk of bias trials will be excluded.  
Publication bias 
No tests were performed to detect publication bias. 
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